

Europäisches Patentamt
European Patent Office
Office européen des brevets



C2

(11) **EP 1 052 254 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
15.11.2000 Bulletin 2000/46

(21) Application number: 99900654.7

(22) Date of filing: 21.01.1999

(51) Int. Cl.⁷: **C07D 239/84**, C07D 215/38,
C07D 401/12, C07D 401/10,
C07D 401/04, C07D 405/12,
C07D 409/04, A61K 31/505,
A61K 31/47

(86) International application number:
PCT/JP99/00215

(87) International publication number:
WO 99/37622 (29.07.1999 Gazette 1999/30)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: 26.01.1998 JP 1306298

(71) Applicant: Eisai Co., Ltd.
Tokyo 112-8088 (JP)


(72) Inventors:
• MIYAZAKI, Kazuki
Tsukuba-shi, Ibaraki 305-0061 (JP)

• TAKASE, Yasutaka
Brookline, MA 02446 (US)
• SAEKI, Takao
Ibaraki 302-0102 (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF

(57) The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same.



Wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group, R¹ represents hydrogen atom, a halogen atom, a C₁₋₆ alkyl group which may be substituted with a halogen atom, a C₁₋₆ alkoxy group which may be substituted with a halogen atom, etc., R² and R³ are the same as or different from and represent hydrogen atom, a C₁₋₆ alkyl group which may have a substituent group, a C₃₋₇ cycloalkyl group which may have a substituent group, etc., R⁴, R⁵, R⁶ and R⁷ are the same as or

different from each other and each represent hydrogen atom, a halogen atom, a C₁₋₆ alkyl group which may be substituted with a halogen atom, a C₃₋₇ cycloalkyl group which may have a substituent group, a C₁₋₆ alkoxy group which may have a substituent group, etc., neighboring R³, R⁴, R⁵ and R⁶ may be combined to form a ring which may be substituted with a C₁₋₆ alkyl group which may contain a heteroatom, L represents a single bond, (a) a C₁₋₆ alkylene group, (b) a C₂₋₆ alkenylene group, (c) a C₂₋₆ alkynylene group, all of which may have a substituent group, or a group represented by the formula -E-G- (wherein E represents oxygen atom, sulfur atom, the formula -CO-, -SO-, -SO₂-, -N(R⁸)- (R⁸ is hydrogen atom, a C₁₋₆ alkyl group or an acyl group), -N(R⁹)-CO- (R⁹ is hydrogen atom or a C₁₋₆ alkyl group), or -(CH₂)_m- which may have a substituent group (m is an integer of 0 to 6), and G represents a sulfonyl group, the formula -N(R¹⁰)- (R¹⁰ represents hydrogen atom, a C₁₋₆ alkyl group or an acyl group) or -(CH₂)_n- (n is an integer of 0 to 6)), and X and Y are the same as or different from each other and each represents nitrogen atom, =CH- or a carbon atom which may be substituted with a C₁₋₆ alkyl group which may have a substituent group, provided that X and Y are not simultaneously carbon atoms which may be substituted with a C₁₋₃ alkyl group.

Description

Technical Field

5 [0001] The present invention relates to a nitrogen-containing heterocyclic compound derivative useful as a phosphodiesterase-4 inhibitor, its salt or hydrates thereof, and a medicament comprising the same. More specifically, it relates to a prophylactic and therapeutic agent comprising a nitrogen-containing heterocyclic compound, its salt or hydrates thereof for inflammatory diseases, asthma, autoimmune disease such as allograft rejection, graft versus host disease, chronic joint rheumatism and multiple sclerosis, sepsis, psoriasis, osteoporosis or diabetes.

Prior Art

10 [0002] In a group of a series of decomposition enzymes called phosphodiesterase (referred to hereinafter as "PDE"), the presence of 7 families of PDE1 to PDE7 is confirmed. One family PDE4 is an enzyme specific to a secondary messenger, cyclic adenosine-3',5'-monophosphate (cyclic AMP), and is known to regulate the concentration of cyclic AMP by decomposition. Cyclic AMP is increased in vivo upon stimulation with hormone, to exhibit a wide variety of physiological actions such as formation of specific enzymes or regulation of metabolic functions, and in e.g. human leukocytes, cyclic AMP has an important role in activation of cells and regulation of immune response. Under this background, the physiological significance of PDE4 has been regarded as important in recent years, and it is expected that


20 a PDE4 inhibitor can work effectively as a prophylactic and therapeutic agent against various diseases in which cyclic AMP is involved. For example, since PDE4 is present widely in mast cells eosinophils monocytes macrophages T-lymphocytes, epithelial cells, and respiratory smooth muscles, there have been proposed the possibility of the PDE4 inhibitor as an anti-asthma agent (Clin. Exp. Allergy, 22, 337-44, 1992) and the possibility of the PDE4 inhibitor as an agent for treating arthritis, cachexia, multiple sclerosis and sepsis on the basis of a report on the inhibition of tumor-necrosis-factor α (TNF α) by the PDE4 inhibitor (Int. J. Immunopharmacol., 15, 409-13, 1993; Int. J. Immunopharmacol., 16, 805-16, 1994). With these findings as the background, a large number of reports on those compounds inhibiting PDE4 have been made. For example, JP-A 5-229987 and JP-A 9-59255 disclose an invention relating to naphthalene compounds as PDE4 inhibitors. On the other hand, JP-B 40-20866 and JP-B 6-192099 disclose an invention relating to quinazoline compounds as inhibitors of production of TNF α .

30 [0003] Heretofore, theophylline is famous as a PDE4 inhibitor, but is poor in specificity for PDE4 and inhibits the PDE family unspecifically, thus bringing about side effects in cardiac blood vessels or in the central system. Further, other PDE4 inhibitors also cause the problems of nausea, emesis, headache etc., and therefore, none of effective PDE4 inhibitors have been created.

Disclosure of Invention

35 [0004] Under these circumstances, the present inventors made extensive study for the purpose of providing a PDE4 inhibitor effective for the inflammatory diseases and immune diseases. As a result, they found that a nitrogen-containing heterocyclic compound having a novel structure, its salt or hydrates thereof, exhibit superior activity as a PDE4 inhibitor, and also that it is useful as an inhibitor of production of TNF α . Further, the present inventors found that the PDE4 inhibitor of the present invention has the action of lowering blood sugar and is useful as a prophylactic and therapeutic agent for diabetes. Thus, they have accomplished the present invention.

40 [0005] That is, the present invention relates to a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same.



Wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom,

the ring B represents:

- 1) a saturated hydrocarbon ring which may have a substituent group,
- 2) an unsaturated hydrocarbon ring which may have a substituent group,
- 3) a saturated heterocyclic ring which may have a substituent group or
- 4) an unsaturated heterocyclic ring which may have a substituent group,

R¹ represents:

- 1) hydrogen atom,
- 2) a halogen atom,
- 3) a C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₁₋₆ alkoxy group which may be substituted with a halogen atom or
- 5) an amino group which may be substituted with C₁₋₆ alkyl group or an acyl group,

R² and R³ are the same as or different from and represent:

- 1) hydrogen atom,
- 2) a C₁₋₆ alkyl group which may have a substituent group,
- 3) a C₃₋₇ cycloalkyl group which may have a substituent group,
- 4) a C₂₋₆ alkenyl group which may have a substituent group or
- 5) an acyl group,

R⁴, R⁵, R⁶ and R⁷ are the same as or different from and represent:

- 1) hydrogen atom,
- 2) a halogen atom,
- 3) a C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₃₋₇ cycloalkyl group which may have a substituent group,
- 5) an aryl group which may have a substituent group,
- 6) a C₁₋₆ alkoxy group which may have a substituent group,
- 7) a C₃₋₇ cycloalkoxy group which may have a substituent group,
- 8) an aryl alkoxy group which may have a substituent group, or
- 9) a C₁₋₆ alkylthio group which may have a substituent group,
- 10) a hydroxyl group,
- 11) an amino group which may be substituted with a C₁₋₆ alkyl group or an acyl group,
- 12) a nitro group,
- 13) a cyano group,
- 14) a carboxyl group or
- 15) a C₁₋₆ alkoxy carbonyl group, or

16) neighboring R^3 , R^4 , R^5 and R^6 may be combined to form a ring which may be substituted with a C_{1-6} alkyl group, and the ring being a ring which may form a heterocyclic ring containing one or more atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom,

5 L represents:

- 1) a single bond,
- 2) a C_{1-6} alkylene group which may have a substituent group,
- 3) a C_{2-6} alkenylene group which may have a substituent group,
- 10 4) a C_{2-6} alkynylene group which may have a substituent group, or
- 5) a group represented by the formula -E-G- (wherein E represents:

- a) an oxygen atom,
- b) a sulfur atom,
- 15 c) formula -CO-,
- d) -SO-,
- e) -SO₂-,
- f) -N(R⁸)- (wherein R⁸ represents hydrogen atom, a C_{1-6} alkyl group or an acyl group),
- g) -N(R⁹)-CO- (wherein R⁹ represents hydrogen atom or a C_{1-6} alkyl group) or
- 20 h) -(CH₂)_m- which may have a substituent group (wherein m is an integer of 0 to 6), and

G represents:

- a) a sulfonyl group,
- 25 b) formula -N(R¹⁰)- (wherein R¹⁰ represents hydrogen atom, a C_{1-6} alkyl group or an acyl group), or
- c) -(CH₂)_n- (wherein n is an integer of 0 to 6)), and X and Y are the same as or different from each other and each represents:

- 1) a nitrogen atom,
- 30 2) =CH- or
- 3) a carbon atom which may be substituted with a C_{1-6} alkyl group which may have a substituent group, provided that X and Y are not simultaneously carbon atoms which may be substituted with a C_{1-3} alkyl group.

35 **[0006]** Preferably, X and/or Y is a nitrogen atom.

[0007] Further, the present invention provides a phosphodiesterase-4 inhibitor comprising the above-mentioned nitrogen-containing heterocyclic compound, its salt or hydrates thereof. In addition, it provides an inhibitor of production of TNF α , comprising the above-mentioned nitrogen-containing heterocyclic compound, its salt or hydrates thereof. Furthermore, it provides a pharmaceutical composition comprising a pharmacologically effective amount of the above-mentioned nitrogen-containing heterocyclic compound, its salt or hydrates thereof and a pharmaceutically acceptable carrier. Also, it provides a method of preventing or treating diseases against which an inhibitory action on phosphodiesterase-4 is effective for therapy, which comprises administering a pharmacologically effective amount of the above-mentioned nitrogen-containing heterocyclic compound, its salt or hydrates thereof to a patient for whom an inhibitory action on phosphodiesterase-4 is effective for therapy. Further, it provides use of the above-mentioned nitrogen-containing heterocyclic compound, its salt or hydrates thereof in production of a phosphodiesterase-4 inhibitor.

45 **[0008]** The present invention also encompasses nitrogen-containing heterocyclic compound shown in the following mode, its salt or hydrates thereof.

[0009] That is, in the formula,

50 the ring A is a monocyclic or bicyclic aryl group which may have a substituent group and a heteroatom, the ring B represents:

- 1) a C_{3-7} cycloalkyl group which may have a substituent group and a heteroatom, or
- 2) a monocyclic or bicyclic unsaturated cycloalkyl group which may have a substituent group and a heteroatom,

55

R¹ represents:

- 1) a hydrogen atom,
- 2) a halogen atom,
- 3) a straight-chain or branched C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₁₋₆ alkoxy group which may be substituted with a halogen atom, or
- 5) an amino group which may be substituted with a C₁₋₆ alkyl or acyl group,

R² and R³ are the same or different and represent:

- 1) hydrogen atom,
- 2) a straight or branched C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 3) a C₃₋₇ cycloalkyl group,
- 4) a C₂₋₄ alkenyl group, or
- 5) an acyl group,

R⁴, R⁵, R⁶ and R⁷ are the same or different and represent:

- 1) hydrogen atom,
- 2) a halogen atom,
- 3) a straight or branched C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₃₋₇ cycloalkyl group,
- 5) an aryl group which may have a substituent group,
- 6) a C₁₋₆ alkoxy group which may be substituted with a halogen atom,
- 7) a C₃₋₇ cycloalkoxy group,
- 8) an aryl alkoxy group which may have a substituent group,
- 9) a C₁₋₆ alkylthio group,
- 10) a hydroxy group,
- 11) an amino group which may be substituted with a C₁₋₆ alkyl group or an acyl group,
- 12) a nitro group,
- 13) a cyano group,
- 14) a carboxyl group or
- 15) a C₁₋₆ alkoxycarbonyl group, or
- 16) neighboring R³, R⁴, R⁵ and R⁶ may be combined to form an alkylene dioxy ring which may be substituted with a C₁₋₃ alkyl group,

L represents:

- 1) a C₁₋₆ alkylene group which may have a substituent group,
- 2) a C₂₋₆ alkenylene group which may have a substituent group,
- 3) a C₂₋₆ alkynylene group which may have a substituent group, or
- 4) formula -E-G-, (wherein E represents:
 - a) an oxygen atom,
 - b) a sulfur atom which may be oxidized,
 - c) an alkylene group represented by the formula -(CH₂)_m-which may have a substituent group, wherein m is 0 or an integer of 1 to 6,
 - d) a group shown in the formula -CO-,
 - e) a group represented by the formula -N(R⁸)- (wherein R⁸ represents hydrogen atom, a C₁₋₆ alkyl group or an acyl group) or
 - f) a group represented by the formula -N(R⁹)- (wherein R⁹ represents a hydrogen atom or a C₁₋₆ alkyl group, and

G represents:

- a) a sulfonyl group,
- b) formula -N(R¹⁰)- (wherein R¹⁰ represents hydrogen atom, a C₁₋₆ alkyl group or an acyl group), or
- c) formula -N(CH₂)_n- (wherein n is 0 or an integer of 1 to 6), provided that when both E and G are alkylene groups, L is a C₁₋₆ alkylene group), and

X and Y are the same as or different from each other and each represent:

- 1) a nitrogen atom, or
- 2) a carbon atom which may be substituted with a C₁₋₆ alkyl group, provided that X and Y are not simultaneously carbon atoms which may be substituted with a C₁₋₃ alkyl group.

Detailed Description of the Invention

[0010] The present invention is as described above, and preferably it is a nitrogen-containing heterocyclic compound of the formula (I), wherein the ring A is a benzene or pyridine ring which may have a substituent group; and the ring B is an unsaturated hydrocarbon ring which may have a substituent group or an unsaturated heterocyclic ring which may have a substituent group, its salt or hydrates thereof, and is a medicament comprising the same.

[0011] More preferably, it is a nitrogen-containing heterocyclic compound of the formula (I), wherein the ring A is a benzene or pyridine ring which may have a substituent group; the ring B is an aromatic hydrocarbon ring which may have a substituent group or an aromatic heterocyclic ring which may have a substituent group; L is a single bond, C₁₋₆ alkylene group, C₂₋₆ alkenylene group, C₂₋₆ alkynylene group, the formula -N(R⁸)-CO-(CH₂)₁- (wherein R⁸ has the same meanings as defined above and 1 is an integer of 0 to 6), -N(R⁸)-SO₂- (wherein R⁸ has the same meanings as defined above), -N(R⁸)-(CH₂)₁- (wherein R⁸ and 1 have the same meanings as defined above) or -CO-N(R¹⁰)- (wherein R¹⁰ has the same meanings as defined above); and both X and Y are nitrogen atoms, its salt or hydrates thereof, and is a medicament comprising the same.

[0012] Further preferably, it is a nitrogen-containing heterocyclic compound of the formula (I), wherein the ring A is a benzene or pyridine ring; the ring B is a C₃₋₇ hydrocarbon ring which may have a substituent group, a benzene ring which may have a substituent group, a naphthalene ring which may have a substituent group, a pyridine ring which may have a substituent group, a pyrrole ring which may have a substituent group, a quinoline ring which may have a substituent group, an imidazopyridine ring which may have a substituent group, an isoindole ring, a phthalimide ring or a benzene ring which may be substituted with an alkylene dioxy group; L is a single bond, -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -CH=CH-, -C≡C-, the formula -NH-CO-, -CO-NH- or -NH-SO₂-; both X and Y are nitrogen atoms; R₂ and R₃ are the same as or different from and represent hydrogen atom or a C₁₋₆ alkyl group which may be substituted with a halogen atom; both R⁴ and R⁷ are hydrogen atoms, R⁵ and R⁶ are the same as or different from and represent a C₁₋₆ alkoxy group which may be substituted with a halogen atom, a C₃₋₇ cycloalkoxy group which may have a substituent group, an aryl group which may have a substituent group or an aryl alkoxy group, its salt or hydrates thereof, and is a medicament comprising the same.

[0013] In the specification, the structural formulae of these compounds may, for convenience' sake, indicate a certain isomer, but the present invention encompasses every possible isomer such as geometric isomer, optical isomer, stereoisomer and tautomer based on asymmetric carbon, which can occur in the structures of these compounds, and mixtures of such isomers, and is not limited to the formulae shown for convenience' sake.

[0014] Hereinafter, the words and phrases used in the specification are described more in detail.

[0015] In the formula (I), the phrase "which may have a substituent group" in the definition of the ring A means that the ring A may be substituted with a substituent group such as hydroxyl group; thiol group; nitro group; morpholino group; thiomorpholino group; halogen atom such as fluorine, chlorine, bromine and iodine; nitrile group; azide group; formyl group; alkyl group such as methyl group, ethyl group, propyl group, isopropyl group and butyl group; alkenyl group such as vinyl group, allyl group and propenyl group; alkynyl group such as ethynyl group, butynyl group and propargyl group; alkoxy group such as methoxy group, ethoxy group, propoxy group and butoxy group corresponding to a lower alkyl group; halogenoalkyl group such as fluoromethyl group, difluoromethyl group, trifluoromethyl group and halogenoethyl group; hydroxyalkyl group such as hydroxymethyl group, hydroxyethyl group and hydroxypropyl group; guanidino group; formimidoyl group; acetoimidoyl group; carbamoyl group; thiocarbamoyl group; carbamoyl alkyl group such as carbamoyl methyl group and carbamoyl ethyl group; alkyl carbamoyl group such as methyl carbamoyl group and dimethyl carbamoyl group; carbamide group; alkanoyl group such as acetyl group; amino group; alkyl amino group such as methyl amino group, ethyl amino group and isopropyl amino group; dialkyl amino group such as dimethyl amino group, methyl ethyl amino group and diethyl amino group; amino alkyl group such as amino methyl group, amino ethyl group and amino propyl group; carboxy group; alkoxycarbonyl group such as methoxycarbonyl group, ethoxycarbonyl group and propoxycarbonyl group; alkoxycarbonyl alkyl group such as methoxycarbonyl methyl group, ethoxycarbonyl methyl group, propoxycarbonyl methyl group, methoxycarbonyl ethyl group, ethoxycarbonyl ethyl group and propoxycarbonyl ethyl group; alkyloxyalkyl group such as methyloxymethyl group, methyloxyethyl group, ethyloxymethyl group and ethyloxyethyl group; alkylthioalkyl group such as methylthiomethyl group, methylthioethyl group, ethylthiomethyl group and ethylthioethyl group; aminoalkyl aminoalkyl group such as aminomethyl aminomethyl group and aminoethyl aminoethyl group; alkyl carbonyloxy group such as methyl carbonyloxy group, ethyl carbonyloxy group and isopropyl carbonyloxy group; cycloalkoxy group such as cyclopropoxy group, cyclobutoxy group, cyclopentoxy group and

cyclohexanoxo group; arylalkoxy group such as phenoxy group, benzyloxy group and phenethyloxy group; arylalkoxy alkoxy alkyl group such as benzyloxy methyl oxymethyl group and benzyloxy ethyloxy ethyl group; hydroxyalkoxyalkyl group such as hydroxyethyloxymethyl group and hydroxyethyloxyethyl group; arylalkoxyalkyl group such as benzyloxyethyl group, benzyloxyethyl group and benzyloxypropyl group; quaternary ammonio group such as trimethyl ammonio group, methyl ethyl methyl ammonio group and triethyl ammonio group; cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group and cyclohexyl group; cycloalkenyl group such as cyclopropenyl group, cyclobutenyl group, cyclopentenyl group and cyclohexenyl group; aryl group such as phenyl group, pyridinyl group, thienyl group, furyl group and pyrrolyl group; alkylthio group such as methylthio group, ethylthio group, propylthio group and butylthio group; arylthio group such as phenylthio group, pyridinylthio group, thienylthio group, furylthio group and pyrrolylthio group; aryl lower alkyl group such as benzyl group, trityl group and dimethoxy trityl group; substituted sulfonyl group such as sulfonyl group, mesyl group and p-toluene sulfonyl group; aryloyl group such as benzoyl group; halogenoaryl group such as fluorophenyl group and bromophenyl group; and oxyalkoxy group such as methylene dioxy group.

[0016] Hereinafter, the phrase "may have a substituent group" in the specification has the same meaning as defined above.

[0017] The heteroatom in the phrase "may have a heteroatom" means an oxygen atom, sulfur atom, nitrogen atom, phosphorus, antimony, bismuth, silicon, germanium, tin and lead, preferably an oxygen atom, sulfur atom and nitrogen atom, more preferably a nitrogen atom.

[0018] Hereinafter, the heteroatom in the phrase "may have a heteroatom" in the specification has the same meaning as defined above.

[0019] The aromatic hydrocarbon ring means a benzene ring, pentalene ring, indene ring, naphthalene ring, azulene ring, heptalene ring and benzocyclooctene ring. The aryl ring means groups based on the above-mentioned aromatic hydrocarbon rings.

[0020] The phrase "aromatic hydrocarbon ring which may have a heteroatom" means an aromatic heterocyclic ring, that is, an aromatic hydrocarbon ring wherein any of 1 to 4 carbon atoms in an aromatic hydrocarbon ring having the same meaning as defined above may be a heteroatom. Examples of such aromatic heterocyclic rings include a pyridine ring, pyrrole ring, imidazole ring, pyrazole ring, pyrazine ring, pyrimidine ring, pyridazine ring, thiophene ring, furan ring, pyran ring, isothiazole ring, isoxazole ring, furazane ring, indolizine ring, indole ring, isoindole ring, indazole ring, purine ring, quinolidine ring, isoquinoline ring, phthalazine ring, naphthylidine ring, quinoxaline ring, quinazoline ring, cinoline ring, pteridine ring, benzothiophene ring, isobenzofuran ring, benzoxazole ring, benzthiazole ring, benzthiadiazole ring, benzimidazole ring, imidazopyridine ring, pyrrolopyridine ring, pyrrolopyrimidine ring and pyridopyrimidine ring, among which a pyridine ring, pyrimidine ring, imidazole ring and quinoline ring are preferable.

[0021] In the specification, the heteroaryl group means groups based on the above-mentioned aromatic heterocyclic rings.

[0022] In the formula (I), the phrase " C_{3-7} saturated hydrocarbon ring which may have a substituent group" in the ring B means e.g. 3- to 7-membered rings such as cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane, and these hydrocarbon rings may have substituent groups having the same meanings as defined above.

[0023] In the specification, the C_{3-7} cycloalkyl group means groups based on the above-mentioned C_{3-7} saturated hydrocarbon rings.

[0024] The saturated heterocyclic ring means rings wherein any of 1 to 4 carbon atoms in the above-mentioned C_{3-7} saturated hydrocarbon rings is a heteroatom, and examples of such rings include aziridine, pyrrolidine, piperidine, imidazolidine, pyrazolidine, piperazine, morpholine, oxasilane and oxathiolane. These saturated heterocyclic rings may have substituent groups having the same meanings as defined above.

[0025] The phrase "unsaturated hydrocarbon ring which may have a substituent group" means a C_{3-7} saturated hydrocarbon ring having the same meanings as defined above except that the ring has a carbon-carbon double bond, and examples of such rings include monocyclic or bicyclic unsaturated hydrocarbon rings such as cyclopropene, cyclobutene, cyclopentene, cyclohexene and cycloheptene or aromatic hydrocarbon rings having the same meanings as defined above.

[0026] The unsaturated heterocyclic ring means an unsaturated hydrocarbon ring having the same meanings as defined above except that any of 1 to 4 carbon atoms therein is a heteroatom, and example of such rings include the same aromatic heterocyclic rings as defined above and unsaturated condensed rings such as phthalimide and succinimide. These unsaturated heterocyclic rings may have substituent groups having the same meanings as defined above.

[0027] In the phrase "may be substituted with a halogen atom" in R^1 in the formula (I), the halogen atom means fluorine, chlorine, bromine, iodine.

[0028] Hereinafter, the halogen atom in the specification has the same meanings as defined above.

[0029] Examples of the C_{1-6} alkyl group include straight or branched C_{1-6} alkyl groups such as methyl group, ethyl group, n-propyl group, i-propyl group, sec-propyl group, n-butyl group, i-butyl group, sec-butyl group, t-butyl group, n-pentyl group, i-pentyl group, sec-pentyl group, t-pentyl group, n-hexyl group, i-hexyl group, 1,2-dimethyl propyl group, 2-

ethyl propyl group, 1-methyl-2-ethyl propyl group, 1-ethyl-2-methyl propyl group, 1,1,2-trimethyl propyl group, 1,2,2-trimethyl propyl group, 1,1-dimethyl butyl group, 2,2-dimethyl butyl group, 2-ethyl butyl group, 1,3-dimethyl butyl group, 2-methyl pentyl group and 3-methyl pentyl group, preferably methyl group, ethyl group, n-propyl group, i-propyl group, sec-propyl group, t-propyl group, n-butyl group, i-butyl group, sec-butyl group, n-pentyl group, i-pentyl group, sec-pentyl group, t-pentyl group, n-hexyl group, i-hexyl group, 1,2-dimethyl propyl group, 2-ethyl propyl group, 1,1-dimethyl butyl group, 2,2-dimethyl butyl group, 2-ethyl butyl group, 1,3-dimethyl butyl group, 2-methyl pentyl group and 3-methyl pentyl group, more preferably methyl group, ethyl group, n-propyl group, i-propyl group, sec-propyl group, n-butyl group, i-butyl group, sec-butyl group, t-butyl group, 1,2-dimethyl propyl group, 2-ethyl propyl group, 1,1-dimethyl butyl group, 2,2-dimethyl butyl group, 2-ethyl butyl group and 1,3-dimethyl butyl group, further preferably methyl group, ethyl group, n-propyl group, i-propyl group, t-propyl group, 1,2-dimethyl propyl group and 2-ethyl propyl group, and most preferably methyl group, ethyl group, n-propyl group, i-propyl group and sec-propyl group.

[0030] Hereinafter, the C_{1-6} alkyl group in the specification has the same meanings as defined in above.

[0031] The " C_{1-6} alkyl group which may be substituted with a halogen atom" means the C_{1-6} alkyl group defined above provided that any of carbon atoms therein may be substituted with the halogen atom defined above, and examples of such groups include a trifluoromethyl group, 2-chloroethyl group, 1,2-dichloroethyl group, 2-bromoethyl group, 3-bromopropyl group, 3,3,3-trifluoropropyl group, 4-chlorobutyl group, 1,1-dimethyl-3-chloroethyl group and 2,2-dimethyl-4-bromobutyl group.

[0032] In the specification, the " C_{1-6} alkyl group which may be substituted with a halogen atom" has the same meanings as defined above.

[0033] The C_{1-6} alkoxy group includes alkoxy groups that correspond to the C_{1-6} alkyl groups defined above, and specifically, this group includes a methoxy group, ethoxy group, n-propoxy group, i-propoxy group, sec-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, t-butoxy group, n-pentyloxy group, i-pentyloxy group, sec-pentyloxy group, t-pentyloxy group, n-hexyloxy group, i-hexyloxy group, 1,2-dimethylpropoxy group, 2-ethylpropoxy group, 1-methyl-2-ethylpropoxy group, 1-ethyl-2-methylpropoxy group, 1,1,2-trimethylpropoxy group, 1,2,2-trimethylpropoxy group, 1,1-dimethylbutoxy group, 2,2-dimethylbutoxy group, 2-ethylbutoxy group, 1,3-dimethylbutoxy group, 2-methylpentyloxy group and 3-methylpentyloxy group. The phrase " C_{1-6} alkoxy group which may be substituted with a halogen atom" means a C_{1-6} alkoxy group in which any of carbon atoms may be substituted with the halogen atom defined above, and examples of such groups include a trifluoromethoxy group, 2-chloroethoxy group, 1,2-dichloroethoxy group, 2-bromoethoxy group, 3-bromopropoxy group, 3,3,3-trifluoropropoxy group, 4-chlorobutyloxy group, 1,1-dimethyl-3-chloroethoxy group and 2,2-dimethyl-4-bromobutyloxy group.

[0034] In the specification, the " C_{1-6} alkoxy group which may be substituted with a halogen atom" has the same meanings as defined above.

[0035] In the phrase "may be substituted with a C_{1-6} alkyl group or acyl group", the acyl group includes e.g. a formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group, acryloyl group, methacryloyl group, crotonyl group, chloroformyl group, pivaloyl group, oxazalo group, methoxalyl group, ethoxalyl group and benzoyl group.

[0036] Hereinafter, the acyl group in the specification has the same meanings as defined above.

[0037] In the phrase "amino group which may be substituted with a C_{1-6} alkyl group or acyl group", the amino group means an amino group which may be substituted with the same C_{1-6} alkyl group or the same acyl group as defined above, and examples of such groups include a N-formyl amino group, N-acetyl amino group, N-propionyl amino group, N-pivaloyl amino group, N-benzoyl amino group, N-methyl-N-formyl amino group, N-methyl-N-benzoyl amino group, N-methyl amino group, N,N-dimethyl amino group, N-methyl-N-ethyl amino group, N-(n-propyl) amino group, N-(i-propyl) amino group and N-(t-butyl) amino group.

[0038] Hereinafter, the "amino group which may be substituted with a C_{1-6} alkyl group or acyl group" in the specification has the same meanings as defined above.

[0039] In the formula (I), the " C_{1-6} alkyl group which may be substituted with a halogen atom", the " C_{3-7} cycloalkyl group" and the "acyl group" in the definition of R^2 and R^3 have the same meanings as defined above.

[0040] Specifically, the " C_{2-6} alkenyl group" means e.g. a vinyl group, allyl group, isopropenyl group, 1-propene-2-yl group, 1-butene-1-yl group, 1-butene-2-yl group, 1-butene-3-yl group, 2-butene-1-yl group and 2-butene-2-yl group.

[0041] In the formula (I), the "halogen atom", the "straight or branched C_{1-6} alkyl group which may be substituted with a halogen atom", the " C_{3-7} cycloalkyl group", the "aryl group which may have a substituent group", the " C_{1-6} alkoxy group which may be substituted with a halogen atom" and the "amino group which may be substituted with a C_{1-6} alkyl group or acyl group" have the same meanings as defined above.

[0042] The phrase " C_{3-7} cycloalkoxy group" means cycloalkoxy groups that correspond to the C_{3-7} cycloalkyl groups defined above, and examples include a cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group and cyclohexyloxy group.

[0043] The phrase "aryl alkoxy group" means an alkoxy group having the same meanings as defined above except that it is substituted with an aryl group having the same meanings as defined above.

[0044] The phrase "C₁₋₆ alkylthio group" means alkylthio groups that correspond to the C₁₋₆ alkyl groups defined above, and examples include a methyl thio group, ethyl thio group, n-propyl thio group, i-propyl thio group, sec-propyl thio group, n-butyl thio group, i-butyl thio group, sec-butyl thio group, t-butyl thio group, 1,2-dimethyl propyl thio group, 2-ethyl propyl thio group, 1,1-dimethyl butyl thio group, 2,2-dimethyl butyl thio group, 2-thyl butyl thio group and 1,3-dimethyl butyl thio group.

[0045] The phrase "C₁₋₆ alkoxy carbonyl group" means alkoxy carbonyl groups that correspond to the C₁₋₆ alkoxy groups defined above, and examples include a methoxy carbonyl group, ethoxy carbonyl group, n-propoxy carbonyl group, i-propoxy carbonyl group, sec-propoxy carbonyl group, n-butoxy carbonyl group, i-butoxy carbonyl group, 1,2-dimethyl propoxy carbonyl group and 2-ethyl propoxy carbonyl group.

[0046] The phrase "neighboring R³, R⁴, R⁵ and R⁶ may be combined to form a ring which may be substituted with a C₁₋₆ alkyl group" means that neighboring groups among the substituent groups R³, R⁴, R⁵ and R⁶ may be linked to one another to form a heterocyclic ring containing one or more atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, and this ring, together with carbon atoms in the benzene ring, forms a 5- to 7-membered ring. Specifically, such a ring includes rings represented by the formula -O-(CH₂)_n-O- (n is an integer of 1 to 3), such as a 2,4-methylene dioxy ring as 5-membered ring, 2,5-ethylene dioxy ring as 6-membered ring and 2,6-propylene dioxy ring as 7-membered ring.

[0047] Further, these alkylene dioxy rings may be substituted with C₁₋₃ alkyl group. The C₁₋₃ alkyl group corresponds to the C₁₋₃ alkyl group out of the C₁₋₆ alkyl group defined above, and examples include a methyl group, ethyl group, n-propyl group, i-propyl group and sec-propyl group.


[0048] In the phrase "C₁₋₆ alkylene group which may have a substituent group" in the definition of L in the formula (I), the alkylene group refers to a divalent group derived from a straight-chain C₁₋₆ saturated hydrocarbon by removing one hydrogen atom from each of both terminal carbon atoms thereof. Specific examples include a methylene group, ethylene group, propylene group, butylene group, pentylene group and hexylene group, preferably methylene group, ethylene group, propylene group, butylene group and pentylene group, more preferably methylene group, ethylene group, propylene group and butylene group, further preferably methylene group and ethylene group.

[0049] In the phrase "C₂₋₆ alkenylene group which may have a substituent group", the alkenylene group means a divalent group, which similar to the above-described alkylene group, is derived from a straight-chain C₂₋₆ unsaturated hydrocarbon having a carbon-carbon double bond by removing one hydrogen atom from each of both terminal carbon atoms thereof. Specific examples include a vinylene group, propenylene group, butenylene group, pentenylene group and hexenylene group, preferably vinylene group, propenylene group, butenylene group and pentenylene group, more preferably vinylene group, propenylene group and butenylene group, further preferably vinylene group and propenylene group.

[0050] In the phrase "C₂₋₆ alkynylene group which may have a substituent group", the alkynylene group refers to a divalent group, which similar to the groups described above, is derived from a straight C₂₋₆ unsaturated hydrocarbon having a carbon-carbon triple bond by removing one hydrogen atom from each of both terminal carbon atoms thereof. Specific examples include an ethynylene group, propynylene group, butynylene group, pentynylene group and hexynylene, preferably ethynylene group, propynylene group, butynylene group and pentynylene group, more preferably ethynylene group, propynylene group and butynylene group, further preferably ethynylene group and propynylene group.

[0051] In the formula -E-G-, E is defined to be an oxygen atom, a sulfur atom, the formula -CO-, -SO-, SO₂-, -N(R⁸)- (wherein, R⁸ represents hydrogen atom, C₁₋₆ alkyl group or acyl group), -N(R⁹)-CO- (wherein, R⁹ represents hydrogen atom or C₁₋₆ alkyl group) or -(CH₂)_m- which may have a substituent group (wherein, m is an integer of 0 to 6), and G is defined to be a sulfonyl group, the formula -N(R¹⁰)- (wherein, R¹⁰ represents hydrogen atom, C₁₋₆ alkyl group or acyl group) or -(CH₂)_n- (wherein, n is an integer of 0 to 6).

[0052] Specifically, the following structures can be mentioned.



[0053] When m is 0 in the above definition, E is a single bond so that the ring A is linked directly to G. When n is 0, G is a single bond so that the ring B is linked directly to E. When m and n are simultaneously 0, L as a whole represents a single bond so that the ring A is linked directly to the ring B. L may be bound to any position of the rings A and B.

[0054] X and Y are the same or different and represent a nitrogen atom, =CH- or a carbon atom which may be substituted with a C₁₋₆ alkyl group which may have a substituent group. The phrase "may be substituted with a C₁₋₆ alkyl group" means that the carbon atom may be substituted with any of the C₁₋₆ alkyl groups defined above.

[0055] However, the compounds represented by the formula (I) do not include those wherein X and Y are simultaneously carbon atoms which may be substituted with a C₁₋₃ alkyl group, its salt or anhydrides thereof. The C₁₋₃ alkyl group in this case means C₁₋₃ alkyl groups out of the C₁₋₆ alkyl groups defined above.

[0056] In the present invention, the salts include e.g. inorganic acid salts such as hydrofluorate, hydrochloride, hydrobromate, hydroiodate, sulfate, nitrate, perchlorate, phosphate, carbonate and bicarbonate; organic carboxylic acid salts such as acetate, maleate, tartrate and fumarate; organic sulfonic acid salts such as methane sulfonate, trifluoromethane sulfonate, ethane sulfonate, benzene sulfonate and toluene sulfonate; amino acid salts such as alginate, aspartate and glutamate; amine salts such as trimethyl amine salt, triethylamine salt, procaine salt, pyridine salt and phenethyl benzyl amine salt; alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as magnesium salt and calcium salt.

[0057] Although the dosage of the medicament according to the present invention is varied depending on the severeness of symptoms, age, sex, body weight, administration form and the type of disease, the medicament is given daily in one portion or in divided portions in a daily dose, per man, of usually about 30 µg to 10 g, preferably 100 µg to 5 µg, more preferably 100 µg to 100 mg for oral administration, or about 30 µg to 1 g, preferably 100 µg to 500 mg, more preferably 100 µg to 30 mg for injection.

[0058] The administration form of the compound of the present invention is not particularly limited and may be administered orally or parenterally in a usual manner. For example, it can be administered as a pharmaceutical preparation in the form of e.g. tablets, powder, granules, capsules, syrups, troches, inhalations, suppositories, injections, ointments, eye ointments, eye drops, nose drops, ear drops, poultices and lotions.

[0059] These pharmaceutical preparations are produced in a usual manner by blending generally used ingredients as starting materials, where ordinarily used fillers, binders, lubricants, coloring agents, taste and odor correctives and as necessary stabilizers, emulsifiers, absorption promoters, surfactants, pH adjusters, preservatives and antioxidants can be used for pharmaceutical manufacturing.


[0060] These ingredients include e.g. animal and vegetable oils such as soybean oil, tallow and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicon resin; silicon oil; surfactants such as polyoxyethylene fatty ester, sorbitan fatty ester, glycerin fatty ester, polyoxyethylene sorbitan fatty ester, polyoxyethylene hardened castor oil and polyoxyethylene polyoxypropylene block copolymer; water-soluble polymers such as hydroethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinyl pyrrolidone and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyvalent alcohols such as glycerin, propylene glycol, dipropyl-

ene glycol and sorbitol; sugars such as glucose and sucrose; and inorganic powder such as silicic anhydride, aluminum magnesium silicate and aluminum silicate, and pure water.

[0061] For example, the compounds represented by the formula (I) can be produced in the following manner.

5 Production Method 1

[0062]



[0063] Wherein, X, Y, R^1 to R^7 , ring A , ring B and L have the same meanings as defined above. Q means a halogen atom such as chlorine, bromine and iodine, or a hydroxyl group. In Production Method 1, Compound (i-1) having a nitro group is converted by reduction reaction into an amine (ii), and then (ii) is reacted with (iii) to give Compound (I-1) wherein L is e.g. $-N(R^9)-CO-(CH_2)_n-$ (R^9 and n have the same meanings as defined above), $-N(R^8)-SO_2-$ (R^8 has the same meanings as defined above), $-N(R^8)-(CH_2)_n-$ (R^8 and n have the same meanings as defined above) etc.


[0064] The reduction reaction for obtaining (ii) from (i-1) can be conducted for example by catalytic hydrogenation with a catalyst, reduction with a metal such as iron and a metal salt, or by a metal-hydrogen complex compound having a Lewis acid or a metal salt combined with sodium borohydride, among which catalytic hydrogenation in a usual manner is most preferable when the compound has substituent groups which are stable even under catalytic hydrogenation. In the case of catalytic hydrogenation, any metal catalyst such as 10 % palladium-carbon powder (hydrate), which allows the reaction to proceed, can be used. The solvent used may be any solvent which does not affect the reaction, and for example, an alcohol type solvent such as ethanol, an ether type solvent such as tetrahydrofuran or a mixed solvent thereof can be mentioned. By adding a tertiary amine such as triethylamine, further good results can also be obtained. If (i-1) has substituent groups which are not suitable for catalytic hydrogenation, the reduction thereof with a metal such as iron is preferable.

[0065] Preferable examples of (iii) are carboxylic acid compounds and sulfonic acid compounds having an eliminating group Q and a ring corresponding to the ring B . For example, a carbonyl chloride compound or a carboxylic acid compound corresponding to the ring B is allowed to react at room temperature to 60 °C for 0.5 to 6 hours in the presence of an organic base such as pyridine and any salt such as potassium carbonate, sodium carbonate and barium carbonate, whereby Compound (I-1) wherein L is $-N(R^9)-CO-(CH_2)_n-$ (R^9 and n have the same meanings as defined above) can be obtained. In other cases where (iii) is an alkyl halide compound, a sulfonyl chloride compound, an isocyanate compound, a 2,5-dimethoxy tetrahydrofuran compound or a phthalic carbaldehyde compound, each of these

compounds is reacted with (ii) whereby Compound (I-1) can be obtained as its corresponding alkyl amino compound, sulfonamide compound, ureido compound, pyrrolyl compound or isoindolynyl compound. The reaction solvent includes e.g. ether type solvents such as tetrahydrofuran and 1,4-dioxane, dimethylformamide, N-methyl-2-pyrrolidine, and a mixed solvent thereof, and the reaction can be conducted in the absence of a solvent. (I-1) can also be produced by reacting (ii) with the carboxylic acid compound in the presence of a dehydrogenation condensation agent and as necessary a tertiary amine such as triethylamine. In this case, further good results can be obtained by adding e.g. 1-hydroxybenzotriazole. The dehydration condensation agent includes e.g. N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and dicyclohexyl carbodiimide, and the solvent includes e.g. acetonitrile, dimethylformamide and N-methyl-2-pyrrolidinone.

Production Method 2

[0066]



[0067] Compound (I), wherein L is a single bond, a C₂₋₆ alkenylene group which may have a substituent group or a C₂₋₆ alkynylene group which may have a substituent group, can be produced by Production Method 2 shown above. In this reaction scheme, Compound (iv) means boric acid, dialkoxo borane, dialkyl borane and a trialkyl tin compound, all of which have a ring corresponding to the ring B, or the corresponding alkene or the corresponding alkyne.


[0068] In this method, (I-2) is reacted with (iv) in the presence of a catalyst. The reaction is conducted at about 40 to 80 °C for approx. 1 to 24 hours in a nitrogen stream, where any solvent which does not affect the reaction, for example a 2-phase solvent composed of an organic solvent such as toluene, tetrahydrofuran and a mixed solvent thereof and 2 M aqueous sodium carbonate, and a mixed solvent of dimethylformamide and triethylamine, can be used. As the catalyst, any palladium complex allowing the reaction to proceed can be used, and tetrakis(triphenyl phosphine) palladium or bis(triphenyl phosphine) palladium chloride is preferably used. By adding copper iodide etc. depending on the case, further good results can be obtained.

[0069] Compound (I-2) obtained in this production method can be easily converted into Compound (I) wherein L is an alkylene chain. That is, Compound (I-2) wherein L is an alkynylene chain is subjected to an ordinarily known reaction of reducing -C≡C-, for example a reaction with a Lindlar catalyst/triethylamine etc., whereby Compound (I) having the desired alkylene chain can be easily obtained.

[0070] Compounds (I-1) and (I-2) in Production Methods 1 and 2 can be produced respectively in synthetic methods known in the art. One of such methods is Production Method 3 below.

Production Method 3

[0071]




[0072] Production Method 3 is a method wherein (v) is reacted in the presence of a catalyst with (vi), that is, boric acid, dialkoxy borane, dialkyl borane or trialkyl tin compound, thus producing (vii), and (vii) is then reacted with an amine to produce the desired product (i). In the reaction scheme, R¹¹ means a substituent group such as nitro group and halogen atom.

[0073] As the catalyst in the reaction of (v) with (vi), a non-valent or divalent palladium complex such as tetrakis(triphenyl phosphine) palladium can be used. The reaction can be conducted in a two-phase solvent of an organic solvent and 2 M aqueous sodium carbonate in a nitrogen stream at about 40 to 80 °C for about 1 to 24 hours. Any solvent which does not affect the reaction can be used as the organic solvent, and for example, toluene, tetrahydrofuran and mixed solvents thereof can be mentioned. The reaction between (vii) and the amine can be conducted in a usual manner with or without the solvent at about 60 to 180 °C for approx. 1 to 24 hours. In this case, any solvent which does not affect the reaction can be used, and preferable examples include alcohol type solvents such as isopropyl alcohol, ether type solvents such as tetrahydrofuran and 1,4-dioxane, dimethylformamide, N-methyl-2-pyrrolidinone, and mixed solvents thereof. In this reaction, further good results can be obtained by adding salts such as potassium carbonate, sodium carbonate and barium carbonate, and tertiary amines such as triethylamine, diisopropyl ethylamine and DBU, among which tertiary amines such as triethylamine, diisopropyl ethylamine and DBU are preferably used.

[0074] In the case of (v) wherein both X and Y are nitrogen atoms, the quinazoline compound (x) corresponding to (v) can be produced by Production Method 4 below.

Production Process 4

[0075]




[0076] In this production method, a reaction product (ix) obtained from (viii) and urea is treated with a chlorinating reagent thereby producing (v). Herein, R^{12} may be a group such as C_{1-6} alkyl group insofar as $-OR^{12}$ can function as an eliminating group. The reaction of (viii) with urea can be conducted with or without a solvent such as N-methyl-2-pyrrolidinone. In the reaction of obtaining (v) from (ix), e.g. a chlorinating reagent such as phosphorus oxychloride and phosphorus pentachloride can be used, and this reaction can be conducted in a solvent such as tertiary amine e.g. diisopropyl ethylamine or N,N-dimethylformamide, which does not adversely affect the reaction.

[0077] In the case of (vii) wherein both X and Y are nitrogen atoms, its corresponding quinazoline compound can be produced in Production Method 5 below.

Production Method 5

[0078]



[0079] R^{11} in (xi) have the same meanings as defined above. The coupling of (x) with (xi) is conducted in the presence of an acid such as Lewis acid in any solvent not affecting the reaction. (xi) represents an aryl carbonyl halide which may have a substituent group, or its carboxylic acid, or heteroaryl carbonyl halide which may have a substituent group, or its carboxylic acids. As the Lewis acid, e.g. tin tetrachloride can be used. The solvent may be e.g. a halogen type solvent such as dichloromethane.

[0080] (xiii) is obtained by nitrating (xii) with a nitrating agent such as nitric acid, a mixed acid consisting of nitric acid and sulfuric acid, metal nitrates such as sodium nitrate and copper nitrate, acetyl nitrate, or nitronium salts such as nitronium tetrafluoroborate. As the nitrating agent, copper nitrate is particularly preferable. The solvent used may be any solvent such as acetic anhydride, which allows the reaction to proceed.


[0081] The reduction reaction of converting (xiii) into (xiv) can be conducted in the same manner as in the reduction reaction of (i-1) in Production Method 1. The reaction of (xiv) with urea can be carried out in a solution or suspension with or without the solvent at about 150 to 200 °C for approx. 1 to 6 hours. The solvent is preferably e.g. N-methyl-2-pyrrolidinone etc.

5 [0082] The reaction of obtaining (xvi) from (xv) can be conducted in a usual manner by treating (xv) with phosphorus oxychloride or phosphorus pentachloride. Although any solvent which does not affect the reaction can be used, tertiary amines such as diisopropyl ethylamine, or N,N-dimethylformamide, is preferably used.

[0083] The above-mentioned compound (xiv) can also be produced in Production Method 6 below.

10 Production Method 6

[0084]




40 [0085] Compound (xvii) can be obtained by treating (xvi) in the same manner as in the reduction reaction of (i-1) in the above Production Method 1. Compound (xviii) can be obtained by treating the resulting (xvii) with the corresponding carbonyl chloride compound or carboxylic acid compound in the same manner as in the acylation reaction for obtaining (I) from (ii) in the above Production Method 1.

45 [0086] The reaction of obtaining (xiv) from (xviii) can be conducted by the transition reaction of (xviii). That is, (xviii) is allowed to react together with a Lewis acid such as aluminum chloride with or without a solvent at about 180 to 250 °C for approx. 0.1 to 2 hours, where any solvent not affecting the reaction can be used.

[0087] A typical process for producing Compound (I) wherein L is $-\text{CO-N}(\text{R}^{10})-$ (R^{10} has the same meanings as defined above) is shown in Production Method 7 below.

Production Example 7

[0088]



[0089] In this process, the desired compound (xxii) is produced by amidation of the -CHO group in (xx). First, the reaction of oxidizing the -CHO group in (xx) into -COOH group can be conducted in a usual manner by use of an usual oxidizing agent. For example, there is a method of reacting (xx) with a Jones reagent at about 0 to 80 °C for approx. 1 to 6 hours in a solvent such as acetone not influencing the reaction. The amidation of the -COOH group in (xxi) can be effected in a usual manner by use of an amino compound corresponding to the ring B and a dehydration condensation agent. For example, Compound (xxi), the amino compound, the dehydration condensation agent and as necessary a tertiary amine such as triethylamine are dissolved in a solvent and reacted at about 0 to 60 °C for approx. 1 to 24 hours, whereby the desired compound can be produced. In this case, further good results can be obtained by adding 1-hydroxybenzotriazole etc. Although the dehydration condensation agent may be any one which allows the reaction to proceed, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride, dicyclohexyl carbodiimide etc. are preferable. Although the solvent may be any solvent which does not influence the reaction, acetonitrile, dimethylformamide, N-methyl-2-pyrrolidinone etc. are preferable. Further, similar results can also be obtained by chlorinating it with thionyl chloride and subsequent reaction with the corresponding amine compound.

[0090] After the reaction is completed, the product can be purified as desired by conventional treatment methods such as column chromatography on silica gel, adsorption resin etc. or recrystallization from a suitable solvent.

[0091] The pharmacological actions of the compound according to the present invention were confirmed by the following test methods.

Test Example 1

[0092]

5 Inhibitory Action on PDE4: PDE4D was cloned from human placental mRNA by PCR techniques, and cDNA after an alternative spliced site (Mol. Cell. Biol., 13, 6558, 1993) was expressed in BHK cells. Two clones of BHK cells expressing PDE4 activity which was 100 or more times as high as endogenous PDE4 activity were obtained, and one of the clones was cultured in a large amount, and its homogenate was used as an enzyme source of PDE4.

10 [0093] 50 mM Tris-HCl (pH 8.0), 0.1 mM EGTA, 0.1 mM MgCl₂, 1 μM [³H]-cGMP (100,000 dpm/tube) or 1 μM [³H]-cAMP (100,000 dpm/tube) was added to the above homogenate, and 0.2 ml of the mixture was incubated at 30 °C for 10 to 20 minutes in the presence or absence of a test compound. The enzyme reaction was stopped by incubating the mixture at 95 °C for 1.5 minutes, and after cooling on ice, 50 μl nucleotidase (10 units/ml) was added thereto and incubated at 30 °C for 10 minutes. 550 μl of AG1-X2 resin slurry (H₂O:resin=2:1) was added to the reaction mixture, then
15 left at 4 °C for 10 minutes and centrifuged (10,000 rpm, 2.5 minutes, 4 °C), and 450 μl of the supernatant was measured for radioactivity.

[0094] The activity was compared in terms of IC₅₀ (concentration of the compound at which 50 % of the enzyme activity is inhibited). IC₅₀ was determined by plotting of the concentration of cAMP as the substrate and the concentration of the compound on logarithmic graph paper. The results shown in Table 1 are the average in triplicate measurements. The test compound was first dissolved in DMSO and then diluted with the above-mentioned buffer for use.
20

Table 1

Ex. No.	PDE4 Inhibition IC ₅₀ (nM)
2	8.5
14	4
17	4.2
18	1.4
21	2.2
30	2.6
31	2.5
32	2.6
34	3.1
44	2.5
45	0.72
49	1.1
51	3.2
52	1.8
53	0.63
54	1.7
56	1.2
58	2.8
60	0.22
61	0.6
62	1.9
63	0.6

Table 1 (continued)

Ex. No.	PDE4 Inhibition IC ₅₀ (nM)
64	0.19
65	2.5

Test Example 2

[0095]

Inhibitory Action on Production of TNF: Human peripheral blood was collected in heparin (1 %) and centrifuged (1000 rpm, 10 minutes, at room temperature) to remove platelet rich plasma, and then the blood sample was mixed with Hank's balanced salt solution (HBSS) (with an equal volume to the removed plasma) containing penicillin (100 units/ml) and streptomycin (100 µg/ml) (referred to hereinafter as "p, s"). Ficoll-paque (Pharmacia) with an volume of 3/5 relative to the sample mixture was layered on the lower layer and centrifuged at 1500 rpm for 30 minutes at room temperature, and the monocyte nucleus fraction was collected. The resulting monocyte nucleus fraction was washed twice with p, s-containing HBSS and prepared as a cell float at a cell density of $2-4 \times 10^6$ cells/ml in p, s-containing RPMI1640 (containing 10 % FCS). 400 µl of the prepared cell float was added to a 48-wells culture plate, and 50 µl LPS (100 ng/ml of saline) and 50 µl of each of compound solutions prepared at various concentrations were added to each well, followed by incubation at 37 °C in a 5 % CO₂ mixed air. After incubation for 18 to 24 hours, the incubated buffer was separated, and TNFα thus released from the cells was measured by an ELISA kit (Amasham).

[0096] The inhibitory action of the compound on production of TNFα was determined in terms of IC₅₀ by plotting the concentrations of the compound and the amount of produced TNFα (% relative to the control) on semilogarithmic graph paper. The control (100 %) for the amount of TNFα produced was obtained by subtracting the amount of TNFα produced in the (basal) group where neither LPS nor the compound was added, from the amount of TNFα produced in the (control) group where the compound was not added. The results are shown in Table 2.

[0097] After the compound was dissolved at a concentration of 10 mM in DMSO, a DMSO solution containing the compound at a concentration which was 1000 times as high as the final concentration, and then the solution was diluted with RPMI1640 containing 10 % FCS and p,s, to prepare a solution containing the compound at a concentration which was 10 times as high as the final concentration. In place of the compound solution, RPMI1640 (1 % DMSO, 10 % FCS) containing p, s was added to the control group and basal group. In place of the LPS solution, physiological saline was added to the basal group.

Table 2

Ex.No.	TNFα Inhibition IC ₅₀ (nM)
2	4.7
14	1.6
18	3.3
32	2.3
49	1.7

Test Example 3

[0098]

Blood Sugar-Depressing Action (ZDF rat): A test compound was suspended in 0.5 % MC, and the suspension was orally administered to an animal once every day for 1 week. After the administration, the rat was allowed to fast for 4 hours, and blood was collected from the tail vein, added immediately to 0.6 M HClO₄ (blood:0.6 M HClO₄=1:9), and centrifuged to give a supernatant which was then measured for glucose level by Glucose CII Test Wako Kit

(Wako Pure Chemical Industries, Ltd., JP). In the table, values in the parentheses under the blood sugar level (mg/dl) indicate glucose levels relative to those (=100 %) before the administration of the test compound.

Table 3

Ex. No.	Before the administration (mg/dl)	After the continuous administration for 1 week (mg/dl)
Control	478.3±38.2 (100)	530.3±69.5 (110.9)
32	478.5± 7.3 (100)	349.3±44.3 (73.0)
62	478.6±24.0 (100)	369.1±37.3 (77.1)


[0099] From the above results, the compound of the present invention is useful as a PDE4 inhibitor, and on the basis of this inhibitory action, the compound is further useful as an inhibitor of production of $\text{TNF}\alpha$. The compound of the present invention is very useful as a prophylactic and therapeutic agent for diseases in which cyclic AMP or $\text{TNF}\alpha$ is involved, such as inflammatory diseases such as arthritis, chronic joint rheumatism and asthma, immune diseases such as autoimmune disease, allograft rejection and graft versus host disease, central diseases such as multiple sclerosis, and sepsis, psoriasis and osteoporosis.

[0100] Further, the present inventors found that the compound of the present invention useful as a PDE4 inhibitor lowers blood sugar levels significantly in animals with diabetes. The compound of the present invention is also very useful as a prophylactic and therapeutic agent against diabetes.

[0101] Hereinafter, the present invention is described in more detail with reference to Production Examples and Examples. However, it goes without saying that the present invention is not limit thereto.

Production Example 1: 2-Chloro-6,7-dimethoxy-4-(3-nitrophenyl)quinazoline

[0102]



[0103] 3.16 g of 3,4-dichloro-6,7-dimethoxy quinazoline, 2.04 g of 3-nitrophenyl boric acid and 1.00 g tetrakis(triphenyl phosphine) palladium were suspended in a mixed solvent of 200 ml toluene and 100 ml of 2 M aqueous sodium carbonate and stirred at 60 °C for 15 hours in a nitrogen stream. The organic layer was recovered, washed with water and then with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=2:1). The product was recrystallized from ethanol to give 3.50 g of the title compound as colorless crystals.


$^1\text{H-NMR}$ (400MHz, CDCl_3) δ : 3.92(3H,s), 4.09(3H,s), 7.19(1H,s), 7.38(1H,s), 7.80(1H,dd,J=8.2,7.7Hz), 8.16(1H,ddd,J=7.7,1.6,1.2Hz), 8.44(1H,ddd,J=8.2,2.1,1.2Hz), 8.68(1H,dd,J=2.1,1.6Hz).

m.p.: 228-230°C

MASS 346(MH^+)

Production Example 2: 4-(3-Biphenyl)-2-chloro-6,7-dimethoxy quinazoline

[0104]




[0105] Starting from 3-biphenyl boric acid (1.45 g) obtained from 3-bromobiphenyl according to the method of *J. Org. Chem.*, 56, 3763, 1991. and 3,4-dichloro-6,7-dimethoxyquinazoline (1.50g), 1.84 g of the title compound was obtained as a colorless crystals in the same manner as in Production Example 1.

¹H-NMR (400MHz, CDCl₃) δ; 3.91(3H,s), 4.08(3H,s), 7.36(1H,s), 7.37(1H,s), 7.39(1H,m), 7.47(2H,m), 7.64(1H,t,J=8.0Hz), 7.65(2H,m), 7.73(1H,dt,J=8.0,1.6Hz), 7.80(1H,dt,J=8.0,1.6Hz), 8.00(1H,t,J=1.6Hz).

Production Example 3: 4-(3-Bromophenyl)-2-chloro-6,7-dimethoxy quinazoline


[0106]



¹H-NMR (400MHz, CDCl₃) δ; 3.92(3H,s), 4.08(3H,s), 7.24(1H,s), 7.35(1H,s), 7.45(1H,dd,J=7.9,7.7Hz), 7.70(1H,ddd,J=7.7,1.4,1.0Hz), 7.77(1H,ddd,J=7.9,2.0,1.0Hz), 7.94(1H,dd,J=2.0,1.4Hz).

Production Example 4: 6,7-Dimethoxy-2-methylamino-4-(3-nitrophenyl)quinazoline

[0107]




[0108] 2.50 g of 2-chloro-6,7-dimethoxy-4-(3-nitrophenyl)quinazoline obtained in Production Example 1, 4.89 g methylamine hydrochloride and 11.0 g triethylamine were suspended in 25 ml 1-methyl-2-pyrrolidinone and stirred at 130 °C for 18 hours in a sealed tube. Ethyl acetate and tetrahydrofuran were added thereto, and the reaction solution was washed with water 5 times and then with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:2). The product was recrystallized from tetrahydrofuran-ethyl acetate to give 1.89 g of the title compound as yellow crystals.

¹H-NMR (400MHZ, CDCl₃) δ; 3.14(3H,d,J=5.0Hz), 3.82(3H,s), 4.05(3H,s), 5.14(1H,br s), 6.97(1H,s), 7.10(1H,s), 7.74(1H,dd,J=8.2,8.0Hz), 8.07(1H,ddd,J=8.0,1.8,1.1Hz), 8.39(1H,ddd,J=8.2,2.1,1.1Hz), 8.62(1H,dd,J=2.1,1.8Hz).
m.p.; 218-220°C
MASS 341 (MH⁺)

Production Example 5: 6,7-Dimethoxy-2-ethylamino-4-(3-nitrophenyl)quinazoline

[0109]




[0110] Starting from 500 mg 2-chloro-6,7-dimethoxy-4-(3-nitrophenyl)quinazoline and 1.18 g ethylamine hydrochloride, 183 mg of the title compound was obtained as yellow crystals in the same manner as in Production Example 4.

¹H-NMR (400MHZ, CDCl₃) δ; 1.31(3H,t,J=7.2Hz), 3.59(2H,m), 3.82(3H,s), 4.04(3H,s), 5.11(1H,br s), 6.96(1H,s), 7.08(1H,s), 7.74(1H,dd,J=8.2,7.7Hz), 8.06(1H,ddd,J=7.7,1.6,1.1Hz), 8.39(1H,ddd,J=8.2,2.2,1.1Hz), 8.62(1H,dd,J=2.2,1.6Hz).
m.p.; 164-166°C
MASS 355 (MH⁺)

Production Example 6: 2-Cyclopropylamino-6,7-dimethoxy-4-(3-nitrophenyl)quinazoline

[0111]



[0112] Starting from 500 mg 2-chloro-6,7-dimethoxy-4-(3-nitrophenyl)quinazoline and 414 mg cyclopropylamine hydrochloride, 134 mg of the title compound was obtained in the same manner as in Production Example 4.


¹H-NMR(400MHz,CDCl₃)δ; 0.62(2H,m), 0.89(2H,m), 2.93(1H,m), 3.83(3H,s), 4.05(3H,s), 5.38(1H,br s), 6.98(1H,s), 7.15(1H,s), 7.74(1H,dd,J=8.2,7.7Hz), 8.07(1H,ddd,J=7.7,1.4,1.1Hz), 8.39(1H,ddd,J=8.2,2.2,1.1Hz), 8.62(1H,dd,J=2.2,1.4Hz).

m.p.; 140-142°C

MASS 367 (MH⁺)

Production Example 7: 4-(3-Aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0113]



[0114] 1.83 g of 6,7-dimethoxy-2-methylamino-4-(3-nitrophenyl) quinazoline obtained in Production Example 4, 200 mg of 10 % palladium-carbon powder (hydrate) and 1.44 g triethylamine were suspended in a mixed solvent of 10 ml ethanol and 10 ml tetrahydrofuran. After the atmosphere was replaced with hydrogen, the mixture was stirred for 15 hours at ordinary pressure at room temperature. The reaction solution was filtered, then the filtrate was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3). The product was recrystallized from hexane-ethyl acetate to give 1.22 g of the title compound as pale yellow crystals.


¹H-NMR(400MHz,CDCl₃)δ; 3.11(3H,d,J=5.2Hz), 3.78-3.84(5H,m), 4.03(3H,s), 5.14(1H,br s), 6.82(1H,dd,J=7.9,2.2Hz), 6.98(1H,dd,J=2.2,1.8Hz), 7.03(1H,dd,J=7.7,1.8Hz), 7.07(1H,s), 7.14(1H,s), 7.30(1H,dd,J=7.9,7.7Hz).

m.p.; 197-199°C

MASS 311 (MH⁺)

Production Example 8: 4-(3-Bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0115]




[0116] 1.50 g of 4-(3-bromophenyl)-2-chloro-6,7-dimethoxyquinazoline obtained in Production Example 3 and 15 ml of 40 % methylamine in methanol were suspended in a mixed solvent of 20 ml isopropanol and 20 ml tetrahydrofuran and stirred at 130 °C for 9 hours in a sealed tube. Ethyl acetate was added thereto, and the reaction solution was washed with water twice and then with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (ethyl acetate). The product was recrystallized from hexane-chloroform to give 1.39 g of the title compound as pale yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 3.11(3H,d,J=5.1Hz), 3.83(3H,s), 4.03(3H,s), 5.15(1H,m), 7.01(1H,s), 7.07(1H,s), 7.41(1H,dd,J=7.9,7.7Hz), 7.62(1H,ddd,J=7.7,1.4,1.0Hz), 7.65(1H,ddd,J=7.9,2.0,1.0Hz), 7.86(1H,dd,J=2.0,1.4Hz).
m.p.: 246-248°C
MASS 374, 376 (MH⁺)

Production Example 9: 1,2-Diethoxybenzene

[0117]




[0118] 15.0 g of 2-ethoxyphenol, 18.0 ml of iodoethane and 30.0 g of potassium carbonate were suspended in 150 ml dimethylformamide, and the mixture was stirred at 80 °C for 30 hours. Ethyl acetate was added thereto, and the mixture was washed with water for five times and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated to give the title compound quantitatively as a red-brown oil.

¹H-NMR(400MHz,CDCl₃)δ; 1.45(6H,t,J=7.0Hz), 4.09(4H,q,J=7.0Hz), 6.89(4H,s).

Production Example 10: 4-(3-Bromobenzoyl)-1,2-diethoxybenzene

[0119]




[0120] 18.9 g of 1,2-diethoxybenzene obtained in Production Example 9 and 22.0 g of 3-bromobenzoyl chloride were dissolved in 100 ml dichloromethane, and 100 ml of 1.0 M tin tetrachloride in dichloromethane was added dropwise thereto under ice-cooling. After the dropwise addition, the mixture was further stirred at room temperature for 15 hours. The reaction solution was poured into ice-cold water to terminate the reaction, and the organic layer was recovered, washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was recrystallized from hexane-ethyl acetate to give 23.8 g of the title compound as colorless crystals.

¹H-NMR (400MHz, CDCl₃) δ; 1.46-1.52(6H,m), 4.13-4.21(4H,m), 6.89(1H,d,J=8.8Hz), 7.32(1H,dd,J=8.8,2.0Hz), 7.35(1H,t,J=7.8Hz), 7.46(1H,d,J=2.0Hz), 7.64-7.71(2H,m), 7.88(1H,t,J=1.6Hz).

Production Example 11: 5-(3-Bromobenzoyl)-1,2-diethoxy-4-nitrobenzene

[0121]




[0122] 4-(3-Bromobenzoyl)-1,2-diethoxybenzene (20.7 g) obtained in Production Example 10 was dissolved in 80 ml of acetic anhydride, and then 4.5 ml of fuming nitric acid was added dropwise into the mixture under ice-cooling. After the dropwise addition, the mixture was further stirred 15 min under ice-cooling. The reaction mixture was poured into ice-cold water to cease the reaction, and then the resulting crystals were collected by filtration, washed with water and then air-dried to give 23.1 g of the title compound as yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 1.50(3H,t,J=7.2Hz), 1.55(3H,t,J=7.2Hz), 4.17(2H,q,J=7.2Hz), 4.25(2H,q,J=7.2Hz), 6.80(1H,s), 7.31(1H,t,J=8.0Hz), 7.62(1H,ddd,J=8.0,1.6,1.2Hz), 7.68(1H,ddd,J=8.0,1.6,1.2Hz), 7.72(1H,s), 7.87(1H,t,J=1.6Hz).

Production Example 12: 4-Amino-5-(3-bromobenzoyl)-1,2-diethoxybenzene

[0123]




[0124] 5-(3-Bromobenzoyl)-1,2-diethoxy-4-nitrobenzene (25.6 g) obtained in Production Example 11 and 16.5 g of iron (powder) were suspended in a mixed solvent of 300 ml of ethanol and 75 ml of acetic acid, and the mixture was heated under reflux for 2 hours. The solvent was evaporated, and then the resulting residue was suspended in ethyl acetate and filtered. The filtrate was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:1). The title compound was obtained quantitatively as yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 1.33(3H,t,J=7.2Hz), 1.48(3H,t,J=7.2Hz), 3.85(2H,q,J=7.2Hz), 4.11(2H,q,J=7.2Hz), 6.17(1H,s), 6.89(1H,s), 7.32(1H,t,J=8.0Hz), 7.51(1H,ddd,J=8.0,2.0,1.2Hz), 7.61(1H,ddd,J=8.0,1.2,0.8Hz), 7.73(1H,dd,J=2.0,0.8Hz).

Production Example 13: 4-(3-Bromophenyl)-6,7-diethoxy-2-quinazoline

[0125]




[0126] 4-Amino-5-(3-bromobenzoyl)-1,2-diethoxybenzene (25.1 g) obtained in Production Example 12 and 50.0 g of urea were suspended in 15 ml of 1-methyl-2-pyrrolidinone, and the mixture was stirred at 200 °C for 1 hour. Water was added thereto, and the resulting crystals were collected by filtration, washed with water and then air-dried to give 23.2 g of the title compound as yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 1.29(3H,t,J=7.2Hz), 1.41(3H,t,J=7.2Hz), 3.91(2H,q,J=7.2Hz), 4.15(2H,q,J=7.2Hz), 5.47(1H,br s), 6.17(1H,s), 6.95(1H,s), 7.54(1H,t,J=8.0Hz), 7.69(1H,dd,J=8.0,1.6Hz), 7.80(1H,dd,J=8.0,1.6Hz), 7.84(1H,t,J=1.6Hz).

Production Example 14: 4-(3-Bromophenyl)-2-chloro-6,7-diethoxyquinazoline

[0127]




[0128] 4-(3-Bromophenyl)-6,7-diethoxy-2-quinazoline (11.5 g) obtained in Production Example 13 was suspended in 90 ml of phosphorous oxychloride, and the mixture was heated under reflux for 1 hour. The solvent was evaporated, and the resulting residue was suspended in dimethylformamide and then poured into ice-cold water. The resulting crystals were collected by filtration, washed with water and then air-dried to give 11.8 g of the title compound as yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ: 1.50(3H,t,J=7.2Hz), 1.57(3H,t,J=7.2Hz), 4.09(2H,q,J=7.2Hz), 4.29(2H,q,J=7.2Hz), 7.21(1H,s), 7.31(1H,s), 7.44(1H,t,J=8.0Hz), 7.66-7.72(2H,m), 7.92(1H,t,J=1.6Hz).

Production Example 15: 4-(3-Bromophenyl)-6,7-diethoxy-2-methylaminoquinazoline

[0129]



[0130] Starting from 12.0 g of 4-(3-bromophenyl)-2-chloro-6,7-diethoxyquinazoline obtained in Production Example 14 and 60 ml of 40% methylamine in methanol, 10.7 g of the title compound was obtained as yellow crystals in the same manner as in Production Example 8.


m.p.: 130-132°C

MASS 402, 404 (MH⁺)

¹H-NMR(400MHz,CDCl₃)δ: 1.44(3H,t,J=7.2Hz), 1.54(3H,t,J=7.2Hz), 3.11(3H,d,J=5.2Hz), 4.00(2H,q,J=7.2Hz), 4.25(2H,q,J=7.2Hz), 5.12(1H,br s), 7.02(1H,s), 7.04(1H,s), 7.40(1H,t,J=8.0Hz), 7.60(1H,ddd,J=8.0,1.6,1.2), 7.64(1H,ddd,J=8.0,1.6,1.2), 7.84(1H,t,J=1.6Hz).

Production Example 16: 2-Chloro-6,7-dimethoxy-4-(3-formylphenyl)quinazoline

[0131]




[0132] Starting from 3.00 g of 3,4-dichloro-6,7-dimethoxyquinazoline and 2.47 g of 3-formylphenyl boric acid, 3.50 g of the title compound was obtained as colorless crystals in the same manner as in Production Example 1.

¹H-NMR(400MHZ,CDCl₃)δ; 3.90(3H,s), 4.08(3H,s), 7.23(1H,s), 7.37(1H,s), 7.78(1H,t,J=7.6Hz), 8.07(1H,dt,J=7.6,1.4Hz), 8.10(1H,dt,J=7.6,1.4Hz), 8.32(1H,t,J=1.4Hz), 10.15(1H,s).


Production Examples 17: 2-Chloro-4-(3-chloroformylphenyl)-6,7-dimethoxyquinazoline

[0133]




[0134] 657 mg of 2-chloro-6,7-dimethoxy-4-(3-formylphenyl)quinazoline obtained in Production Example 16 was converted into a carboxylic acid compound by use of Jones reagent and then reacted with thionyl chloride in a usual manner to give 620 mg of the title compound as pale yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 3.92(3H,s), 4.09(3H,s), 7.21(1H,s), 7.39(1H,s), 7.77(1H,t,J=8.0Hz), 8.15(1H,d,J=8.0Hz), 8.32(1H,d,J=8.0Hz), 8.56(1H,m).

Production Example 18: 6,7-Dimethoxy-4-(3-formylphenyl)-2-methylaminoquinazoline**[0135]**

[0136] Starting from 1.50 g of 2-chloro-6,7-dimethoxy-4-(3-formylphenyl)quinazoline and 15 ml of 40% methylamine in methanol, 1.00 g of the title compound was obtained as yellow crystals in the same manner as in Production Example 8.

¹H-NMR(400MHz,CDCl₃)δ; 3.14(3H,d,J=4.8Hz), 3.80(3H,s), 4.04(3H,s), 5.13(1H,br s), 6.99(1H,s), 7.09(1H,s), 7.72(1H,t,J=7.6Hz), 7.98(1H,dt,J=7.6,1.4Hz), 8.05(1H,dt,J=7.6,1.4Hz), 8.24(1H,t,J=1.4Hz), 10.13(1H,s).


Production Example 19: 6-Benzyloxy-2,4-dichloro-7-methoxyquinazoline**[0137]**

[0138] 3.16 g of 6-benzyloxy-7-methoxy-2,4-quinazolidione obtained by esterifying 5-benzyloxy-4-methoxy-2-nitrobenzoic acid in a usual manner, then reducing its nitro group and cyclizing it with urea, and 10 ml N,N-diisopropyl ethylamine were suspended in 90 ml phosphorus oxychloride, and the mixture was heated under reflux for 1 hour. The solvent was evaporated, and then ethyl acetate was added to the resulting residue which was then washed with water 5 times and with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated, whereby the title compound was obtained quantitatively as yellow crystals.

¹H-NMR (400MHz, CDCl₃) δ; 4.05(3H,s), 5.31(2H,s), 7.29(1H,s), 7.34-7.45(4H,m), 7.49-7.52(2H,m),

Production Example 20: 2-Amino-4-(3-bromophenyl)-6,7-dimethoxyquinazoline

[0139]




[0140] 3.66 g of 5-(3-bromobenzoyl)-1,2-dimethoxy-4-nitrobenzene, which was obtained from 1,2-dimethoxybenzene through the processes in Production Example 10 and then in Production Example 11 was subjected in a usual manner to Wittig-Horner reaction with diethyl cyanomethyl phosphonate, and the resulting crude product and 2.23 g iron were suspended in 40 ml methanol, and 20 ml conc. hydrochloric acid was added dropwise thereto. After the dropwise addition, the mixture was heated under reflux for 8 hours. The solvent was evaporated, then water was added to the residue, and the resulting crystals were collected by filtration. The crystals were returned to the free compound, and purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3) to give 950 mg of the title compound as colorless crystals.

¹H-NMR(400MHz,CDCl₃)δ; 3.80(3H,s), 4.01(3H,s), 4.59(2H,m), 6.53(1H,s), 6.93(1H,s), 7.15(1H,s), 7.36-7.44(2H,m), 7.61(1H,m), 7.65(1H,dd,J=2.0,0.4Hz).

Example 1: 4-(3-Benzoylamino-phenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0141]




[0142] 310 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7, 155 mg benzoyl chloride and 119 mg pyridine were suspended in 20 ml tetrahydrofuran, and the mixture was stirred at room temperature for 30 minutes. After ethyl acetate was added thereto, it was washed with saturated aqueous sodium bicarbonate thrice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3). The product was recrystallized from hexane-ethyl acetate to give 343 mg of the title compound as yellow crystals.

¹H-NMR(400MHz,CDCl₃)δ; 3.12(3H,d,J=4.9Hz), 3.88(3H,s), 4.03(3H,s), 5.12(1H,m), 7.07(1H,s), 7.22(1H,s), 7.48-7.59(5H,m), 7.79(1H,ddd,J=7.7,2.0,1.6Hz), 7.86-7.91(2H,m), 7.96(1H,br s), 8.00(1H,dd,J=2.0,1.4Hz).

m.p.; 201-203°C
MASS 415 (MH⁺)

Example 2: 6,7-Dimethoxy-2-methylamino-4-[3-(4-pyridine carbonylamino)phenyl]quinazoline

[0143]




[0144] Starting from 196 mg of isonicotinoyl chloride, 220 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.

¹H-NMR(400MHz,CDCl₃)δ; 3.11(3H,d,J=4.9Hz), 3.86(3H,s), 4.02(3H,s), 5.13(1H,m), 7.07(1H,s), 7.19(1H,s), 7.52-7.58(2H,m), 7.71 (2H,dd,J=4.4,1.7Hz), 7.77(1H,ddd,J=6.7,2.2,1.5Hz), 8.00(1H,dd,J=1.5,1.0Hz), 8.11(1H,br s), 8.79(2H,dd,J=4.4,1.7Hz).

m.p.; 228-230°C
MASS 416 (MH⁺)

Example 3: 6,7-Dimethoxy-2-methylamino-4-[3-(2-pyridinecarbonylamino)phenyl]quinazoline

[0145]




[0146] Starting from 196 mg of picolinoyl chloride, 298 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.

¹H-NMR(400MHz,CDCl₃)δ; 3.13(3H,d,J=5.0Hz), 3.86(3H,s), 4.03(3H,s), 5.16(1H,m), 7.08(1H,s), 7.22(1H,s), 7.47-7.53(2H,m), 7.56(1H,dd,J=8.0,7.7Hz), 7.88-7.94(2H,m), 8.16(1H,dd,J=2.0,1.4Hz), 8.30(1H,ddd,J=7.9,1.3,0.9Hz), 8.62(1H,ddd,J=4.4,1.6,0.9Hz), 10.16(1H,br s).

m.p.; 175-177°C
MASS 416 (MH⁺)

Example 4: 6,7-Dimethoxy-2-methylamino-4-[3-(3-pyridinecarbonylamino)phenyl]quinazoline

[0147]




[0148] Starting from 196 mg of picolinoyl chloride, 263 mg of the title compound was obtained as yellow crystals in the same manner as in Example 1.

¹H-NMR(400MHz,CDCl₃)δ; 2.91(3H,d,J=4.6Hz), 3.76(3H,s), 3.93(3H,s), 6.97-7.05(2H,m), 7.18(1H,s), 7.47-7.62(3H,m), 7.90(1H,ddd,J=7.2,2.2,0.7Hz), 8.21(1H,dd,J=2.2,1.4Hz), 8.32(1H,ddd,7.7,2.2,1.6Hz), 8.78(1H,dd,J=4.7,2.2Hz), 9.13(1H,d,J=1.6Hz), 10.63(1H,br s).

m.p.; 251-253°C
MASS 416 (MH⁺)

Example 5: 6,7-Dimethoxy-2-methylamino-4-[3-(3,4-methylenedioxybenzoylamino)phenyl]quinazoline

[0149]




[0150] Starting from 369 mg of piperonyl chloride, 466 mg of the title compound was obtained as yellow crystals in the same manner as in Example 1.

¹H-NMR(400MHz, CDCl₃)δ; 3.12(3H,d,J=4.9Hz), 3.87(3H,s), 4.03(3H,s), 5.12(1H,m), 6.06(2H,s), 6.88(1H,d,J=8.0Hz), 7.07(1H,s), 7.21(1H,s), 7.37(1H,d,J=1.8Hz), 7.41(1H,dd,J=8.0,1.8Hz), 7.48(1H,ddd,J=7.8,1.4,1.2Hz), 7.53(1H,dd,J=8.0,7.8Hz), 7.75(1H,ddd,J=8.0,2.0,1.2Hz), 7.83(1H,br s), 7.97(1H,dd,J=2.0,1.4Hz).

m.p.; 205-207°C
MASS 459 (MH⁺)

Example 6: 6,7-Dimethoxy-2-methylamino-4-[3-(phenylacetyl-amino)phenyl]quinazoline

[0151]




[0152] Starting from 155 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7 and 154 mg of phenylacetyl chloride, 184 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.

¹H-NMR (400MHz,CDCl₃)δ; 3.09(3H,d,J=5.1Hz), 3.76(2H,s), 3.82(3H,s), 4.02(3H,s), 5.11(1H,m), 7.05(1H,s), 7.11(1H,s), 7.21(1H,br s), 7.30-7.47(7H,m), 7.60-7.68(2H,m).
m.p.; 175-177°C
MASS 429 (MH⁺)

Example 7: 6,7-Dimethoxy-2-methylamino-4-[3-(3-phenylpropanoyl-amino)phenyl]quinazoline

[0153]




[0154] Starting from 169 mg of 3-phenylpropanoyl chloride, 176 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz,CDCl₃)δ; 2.68(2H,t,J=7.5 Hz), 3.06(2H,t,J=7.5Hz), 3.11(3H,d,J=4.9Hz), 3.85(3H,s), 4.03(3H,s), 5.11(1H,m), 7.06(1H,s), 7.12-7.32(7H,m), 7.42-7.48(2H,m), 7.54(1H,ddd,J=7.5,5.4,0.4 Hz), 7.81(1H,dd,J=0.8,0.4Hz).
m.p.; 180-182°C
MASS 443 (MH⁺)

Example 8: 4-[3-(2-Chlorobenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0155]




[0156] Starting from 175 mg of 2-chlorobenzoyl chloride, 200 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ: 3.12(3H,d,J=4.9Hz), 3.87(3H,s), 4.03(3H,s), 5.16(1H,m), 7.08(1H,s), 7.22(1H,s), 7.36-7.48(3H,m), 7.50-7.58(2H,m), 7.75-7.80(2H,m), 8.02(1H,br s), 8.05(1H,dd,J=0.8,0.4Hz).
m.p.: 197-199°C
MASS 449 (MH⁺)

Example 9: 4-[3-(3-Chlorobenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0157]




[0158] Starting from 175 mg of 3-chlorobenzoyl chloride, 200 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ: 3.12(3H,d,J=4.7Hz), 3.87(3H,s), 4.03(3H,s), 5.49(1H,m), 7.08(1H,s), 7.21(1H,s), 7.43(1H,dd,J=8.0,7.6Hz), 7.50-7.57(3H,m), 7.72-7.78(2H,m), 7.87(1H,dd,J=2.0,1.6Hz), 7.97-8.02(2H,m).
m.p.: 124-126°C
MASS 449 (MH⁺)

Example 10: 4-[3-(4-Chlorobenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0159]




[0160] Starting from 175 mg of 4-chlorobenzoyl chloride, 217 mg of the title compound was obtained as yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.7Hz), 3.87(3H,s), 4.03(3H,s), 5.74(1H,m), 7.07(1H,s), 7.20(1H,s), 7.43-7.47(2H,m), 7.48-7.55(2H,m), 7.75(1H,ddd,J=7.2,2.2,1.8Hz), 7.80-7.84(2H,m), 8.04(1H,br s), 8.07(1H,dd,J=1.8,1.4Hz).
m.p.; 193-195°C
MASS 449 (MH⁺)

Example 11: 6,7-Dimethoxy-4-[3-(2-methoxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0161]




[0162] Starting from 171 mg of 2-methoxybenzoyl chloride, 178 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 4.03(3H,s), 4.06(3H,s), 5.17(1H,m), 7.05(1H,dd,J=8.2,0.8Hz), 7.08(1H,s), 7.15(1H,ddd,J=8.0,7.2,0.8Hz), 7.22(1H,s), 7.44-7.55(3H,m), 7.86(1H,ddd,J=7.9,2.0,1.2Hz), 7.98(1H,dd,J=2.0,1.8Hz), 8.29(1H,dd,J=8.0,1.8Hz), 9.92(1H,br s).
m.p.; 194-196°C
MASS 445 (MH⁺)

Example 12: 6,7-Dimethoxy-4-[3-(3-methoxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0163]



[0164] Starting from 171 mg of 3-methoxybenzoyl chloride, 187 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.


¹H-NMR (400MHz, CDCl₃) δ: 3.12(3H,d,J=4.7Hz), 3.87(3H,s), 3.88(3H,s), 4.03(3H,s), 5.24(1H,m), 7.06-7.12(2H,m), 7.22(1H,s), 7.38-7.42(2H,m), 7.45(1H,dd,J=1.8,1.4Hz), 7.50(1H,ddd,J=7.7,1.4,1.4Hz), 7.54(1H,dd,J=7.9,7.7Hz), 7.79(1H,ddd,J=7.9,1.8,1.4Hz), 7.95(1H,br s), 8.00(1H,dd,J=1.8,1.4Hz).

m.p.: 193-195°C

MASS 445 (MH⁺)

Example 13: 6,7-Dimethoxy-4-[3-(4-methoxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0165]



[0166] Starting from 171 mg of 4-methoxybenzoyl chloride, 178 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.


¹H-NMR (400MHz, CDCl₃)δ: 3.11(3H,d,J=5.0Hz), 3.87(3H,s), 3.88(3H,s), 4.02(3H,s), 5.14(1H,m), 6.95-7.00(2H,m), 7.07(1H,s), 7.22(1H,s), 7.48(1H,ddd,J=7.7,1.4,1.4Hz), 7.53(1H,dd,J=7.9,7.7Hz), 7.78(1H,ddd,J=7.9,2.0,1.4Hz), 7.83-7.88(2H,m), 7.90(1H,brs), 7.97(1H,dd,J=2.0,1.4Hz).

m.p.: 219-221°C

MASS 445 (MH⁺)

Example 14: 6,7-Dimethoxy-4-[3-(3,4-dimethoxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0167]




[0168] Starting from 171 mg of 4-methoxybenzoyl chloride, 178 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=4.9Hz), 3.87(3H,s), 3.95(3H,s), 3.96(3H,s), 4.03(3H,s), 5.15(1H,m), 6.92(1H,d,J=8.4Hz), 7.07(1H,s), 7.21(1H,s), 7.41(1H,dd,J=8.4,2.0Hz), 7.46-7.51(2H,m), 7.54(1H,dd,J=7.9,7.7Hz), 7.82(1H,ddd,J=7.9,2.0,1.4Hz), 7.92(1H,br s), 7.96(1H,dd,J=2.0,1.4Hz).
m.p.; 128-130°C
MASS 475 (MH⁺)

Example 15: 4-[3-(3,4-Dichlorobenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0169]




[0170] Starting from 210 mg of 3,4-dichlorobenzoyl chloride, 183 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 4.04(3H,s), 5.68(1H,m), 7.08(1H,s), 7.21(1H,s), 7.51-7.59(3H,m), 7.70(1H,dd,J=8.4,2.1Hz), 7.74(1H,ddd,J=7.9,2.0,1.4Hz), 7.96-8.02(3H,m).
m.p.; 134-136°C
MASS 483 (MH⁺)

Example 16: 4-(3-Cyclopropanoylamino)phenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0171]




[0172] Starting from 105 mg of cyclopropanecarbonyl chloride, 152 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 0.84-0.90(2H,m), 1.08-1.12(2H,m), 1.48-1.55(1H,m), 3.11(3H,d,J=4.9Hz), 3.83(3H,s), 4.02(3H,s), 5.12(1H,m), 7.06(1H,s), 7.16(1H,s), 7.40-7.53(3H,m), 7.65(1H,ddd,J=7.9,2.0,1.4Hz), 7.86(1H,dd,J=2.0,1.4Hz).

m.p.; 205-207°C
MASS 379 (MH⁺)

Example 17: 4-{3-(3-Cyclopentyloxy-4-methoxybenzoylamino)phenyl}-6,7-dimethoxy-2-methylaminoquinazoline

[0173]




[0174] Starting from 255 mg of 3-cyclopentyloxy-4-methoxybenzoyl chloride, 202 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 1.57-1.67(2H,m), 1.80-2.05(6H,m), 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 3.91(3H,s), 4.03(3H,s), 4.88(1H,m), 5.15(1H,m), 6.90(1H,d,J=8.4Hz), 7.07(1H,s), 7.21(1H,s), 7.38(1H,dd,J=8.4,2.2Hz), 7.46-7.50(2H,m), 7.53(1H,dd,J=7.9,7.7Hz), 7.80(1H,ddd,J=7.9,2.0,1.4Hz), 7.90(1H,br s), 7.96(1H,dd,J=2.0,1.4Hz).

m.p.; 129-131°C
MASS 529 (MH⁺)

Example 18: 4-[3-(3-Chloro-4-methoxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0175]




[0176] Starting from 205 mg of 3-chloro-4-methoxybenzoyl chloride, 152 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.7Hz), 3.87(3H,s), 3.97(3H,s), 4.03(3H,s), 5.32(1H,m), 6.99(1H,d,J=8.6Hz), 7.07(1H,s), 7.21(1H,s), 7.48-7.56(2H,m), 7.74-7.85(2H,m), 7.90-7.93(2H,m), 7.98(1H,dd,J=2.0,1.4Hz).
m.p.; 130-132°C
MASS 479 (MH⁺)

Example 19: 6,7-Dimethoxy-4-methylamino-4-[3-(3,4,5-trimethoxybenzoylamino)phenyl]quinazoline

[0177]




[0178] Starting from 231 mg of 3,4,5-trimethoxybenzoyl chloride, 173 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 6.

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.8Hz), 3.86(3H,s), 3.91(3H,s), 3.93(6H,s), 4.03(3H,s), 5.24(1H,m), 7.08(1H,s), 7.09(2H,s), 7.22(1H,s), 7.49(1H,ddd,J=7.7,1.4,1.4Hz), 7.55(1H,dd,J=7.9,7.7Hz), 7.83(1H,ddd,J=7.9,2.0,1.4Hz), 7.90-7.94(2H,m).
m.p.; 122-124°C
MASS 505 (MH⁺)

Example 20: 4-[3-(4-Benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0179]




[0180] Starting from 4-benzyloxybenzoyl chloride, 516 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.

¹H-NMR (400MHz, CDCl₃)δ: 3.12(3H,d,J=4.8Hz), 3.88(3H,s), 4.03(3H,s), 5.12-5.16(3H,m), 7.04-7.09(3H,m), 7.23(1H,s), 7.32-7.46(5H,m), 7.49(1H,ddd,J=7.6,1.4,1.4Hz), 7.54(1H,dd,J=7.8,7.6Hz), 7.77(1H,ddd,J=7.8,1.8,1.4Hz), 7.83-7.88(3H,m), 7.98(1H,dd,J=1.8,1.4Hz).
m.p.; 110-112°C
MASS 521 (MH⁺)

Example 21: 6,7-Dimethoxy-4-[3-(4-hydroxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0181]




[0182] 388 mg of 4-[3-(4-benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 20 and 200 mg of 10 % palladium-carbon powder (hydrate) were suspended in a mixed solvent of 10 ml ethyl acetate and 10 ml tetrahydrofuran. After the atmosphere was replaced with hydrogen, the mixture was stirred for 3 days at ordinary pressure at room temperature. The reaction solution was filtered, and the filtrate was evaporated. Then, the crude product was recrystallized from hexane-ethyl acetate to give 278 mg of the title compound as pale yellow crystals.

¹H-NMR (400MHz, CDCl₃)δ: 3.12(3H,d,J=4.8Hz), 3.85(3H,s), 4.02(3H,s), 5.19(1H,m), 6.82-6.90(2H,m), 7.08(1H,s), 7.18(1H,s), 7.43-7.54(2H,m), 7.69-7.84(4H,m), 7.98(1H,dd,J=0.8,0.4Hz).
m.p.; 178-180°C

MASS 431 (MH⁺)Example 22: 4-[3-(3-Benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0183]



[0184] Starting from 3-benzyloxybenzoyl chloride, 518 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.


m.p.; 110-112°C

MASS 521 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=4.8Hz), 3.87(3H,s), 4.03(3H,s), 5.14(2H,s), 5.31(1H,m), 7.08(1H,s), 7.17(1H,ddd,J=6.5,2.8,2.2Hz), 7.22(1H,s), 7.30-7.47(7H,m), 7.49-7.57(3H,m), 7.77(1H,ddd,J=8.0,2.0,1.2Hz), 7.91(1H,br s), 8.01(1H,dd,J=2.0,1.4Hz).

Example 23: 6,7-Dimethoxy-4-[3-(3-hydroxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0185]



[0186] Starting from 448 mg of 4-[3-(3-benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 22, 220 mg of the title compound was obtained as colorless crystals in the same manner as in Example 21.


¹H-NMR (400MHz, CDCl₃)δ; 2.90(3H,d,J=4.8Hz), 3.76(3H,s), 3.93(3H,s), 6.96-7.03(3H,m), 7.19(1H,s), 7.39-7.46(4H,m), 7.54(1H,dd,J=8.2,7.6Hz), 7.87(1H,ddd,J=8.2,2.0,1.2Hz), 7.54(1H,dd,J=2.0,1.6Hz), 9.76(1H,s), 10.37(1H,s).

m.p.; 265-267°C

MASS 431 (MH⁺)

Example 24: 4-[3-(2-Benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0187]




[0188] Starting from 2-benzyloxybenzoyl chloride, 500 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.

¹H-NMR (400MHz, CDCl₃)δ; 3.15(3H,d,J=4.8Hz), 3.79(3H,s), 4.06(3H,s), 5.13(1H,m), 5.21(2H,s), 7.03-7.09(2H,m), 7.11(1H,s), 7.13-7.21(2H,m), 7.23-7.31(3H,m), 7.35(1H,ddd,J=7.7,1.4,1.4Hz), 7.39(1H,dd,J=7.9,7.7Hz), 7.46-7.49(2H,m), 7.53(1H,ddd,J=8.2,2.4,1.8Hz), 7.53(1H,ddd,J=7.9,1.4,1.8Hz), 8.34(1H,dd,J=7.8,1.8Hz), 10.15(1H,br s).
m.p.; 192-194°C
MASS 521 (MH⁺)

Example 25: 6,7-Dimethoxy-4-[3-(2-hydroxybenzoylamino)phenyl]-2-methylaminoquinazoline

[0189]




[0190] Starting from 388 mg of 4-[3-(2-benzyloxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 24, 278 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 21.

¹H-NMR (400MHz, CDCl₃)δ; 2.91(3H,d,J=4.7Hz), 3.75(3H,s), 3.93(3H,s), 6.95-7.08(4H,m), 7.18(1H,s), 7.42-7.53(2H,m), 7.57(1H,dd,J=8.0,7.6Hz), 7.81(1H,ddd,J=8.0,2.0,1.2Hz), 7.96(1H,dd,J=8.0,1.6Hz), 8.17(1H,dd,J=2.0,1.6Hz), 10.57(1H,s), 11.72(1H,br s).
m.p.; 212-214°C
MASS 431 (MH⁺)

Example 26: 6,7-Dimethoxy-2-methylamino-4-[3-(4-methylthiobenzoylamino)phenyl]quinazoline

[0191]



[0192] Starting from 930 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7 and 4-methylthiobenzoyl chloride, 1.23 g of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.


¹H-NMR (400MHz, CDCl₃)δ; 2.53(3H,s), 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 4.03(3H,s), 5.12(1H,m), 7.07(1H,s), 7.22(1H,s), 7.30-7.34(2H,m), 7.49(1H,ddd,J=7.7,1.4,1.0Hz), 7.54(1H,dd,J=7.9,7.7Hz), 7.76-7.82(3H,m), 7.90(1H,br s), 7.98(1H,dd,J=1.8,1.4Hz).

m.p.; 209-211°C

MASS 461 (MH⁺)

Example 27: 6,7-Dimethoxy-2-methylamino-4-[3-(4-methylsulfinylbenzoylamino)phenyl]quinazoline

[0193]



[0194] 460 mg of 6,7-dimethoxy-2-methylamino-4-[3-(4-methylthiobenzoylamino)phenyl]quinazoline obtained in Example 26 was dissolved in 1 ml chloroform, and a solution of containing 246 mg 3-chloroperbenzoic acid dissolved in 1 ml chloroform was added dropwise thereto under ice-cooling. After the dropwise addition, the mixture was further stirred at 0 °C for 15 minutes. Ethyl acetate was added thereto, and it was washed with saturated aqueous sodium bicarbonate twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (methanol:ethyl acetate=1:20). The product was recrystallized from hexane-ethyl acetate to give 253 mg of the title compound as yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ; 2.74(3H,s), 3.11(3H,d,J=5.0Hz), 3.87(3H,s), 4.02(3H,s), 5.16(1H,m), 7.07(1H,s), 7.22(1H,s), 7.50-7.59(2H,m), 7.68-7.72(2H,m), 7.85(1H,ddd,J=7.9,1.8,1.4Hz), 7.98-8.02(2H,m), 8.06(1H,dd,J=1.8,1.4Hz), 8.51(1H,br s).

m.p.; 246-248°C

MASS 477 (MH⁺)

Example 28: 6,7-Dimethoxy-2-methylamino-4-[3-(4-methylsulfonylbenzoylamino)phenyl]quinazoline

[0195]



[0196] Starting from 230 mg of 6,7-dimethoxy-2-methylamino-4-[3-(4-methylthiobenzoylamino)phenyl]quinazoline obtained in Example 26, 124 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 27.


¹H-NMR (400MHz, CDCl₃)δ; 3.09(3H,s), 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 4.03(3H,s), 5.13(1H,m), 7.08(1H,s), 7.21(1H,s), 7.53-7.59(2H,m), 7.85(1H,ddd,J=7.9,1.8,1.4Hz), 8.02-8.11(6H,m).

m.p.; 277-279°C

MASS 493 (MH⁺)

Example 29: 4-[3-(6-Chloronicotinoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0197]



[0198] Starting from 6-chloronicotinoyl chloride obtained by chlorinating 965 mg of 6-chloronicotinoic acid with thionyl chloride, 1.44 g of the title compound was obtained as colorless crystals in the same manner as in Example 26.

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.9Hz), 3.86(3H,s), 4.02(3H,s), 5.13(1H,m), 7.07(1H,s), 7.19(1H,s), 7.47(1H,dd,J=8.5,0.8Hz), 7.51-7.58(2H,m), 7.76(1H,ddd,J=7.9,2.0,1.4Hz), 7.98(1H,dd,J=2.0,1.4Hz) 8.03(1H,br s),


8.17(1H,dd,J=8.5,2.6Hz), 8.87(1H,dd,J=2.6,0.8).

m.p.; 157-159°C

MASS 450 (MH⁺)

5 Example 30: 6,7-Dimethoxy-4-[3-(6-dimethylaminonicotinoylamino)phenyl]-2-methylaminoquinazoline

[0199]



25

[0200] 225 mg of 4-[3-(6-chloronicotinoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 29, 122 mg dimethylamine hydrochloride and 304 mg triethylamine were suspended in a mixed solvent of 5 ml isopropanol and 5 ml tetrahydrofuran and stirred at 130 °C for 18 hours in a sealed tube. Ethyl acetate was added thereto, and it was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3). The product was recrystallized from hexane-ethyl acetate to give 185 mg of the title compound as pale yellow crystals.

30

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=5.0Hz), 3.17(6H,s), 3.87(3H,s), 4.03(3H,s), 5.14(1H,m), 6.54(1H,dd,J=8.9,0.6Hz), 7.07(1H,s), 7.22(1H,s), 7.46(1H,ddd,J=7.7,1.4,1.2Hz), 7.52(1H,dd,J=7.9,7.7Hz), 7.75-7.79(2H,m), 7.94-7.99(2H,m), 8.70(1H,dd,J=2.6,0.6Hz).


35

m.p.; 149-151°C

MASS 459 (MH⁺)

40 Example 31: 6,7-Dimethoxy-2-methylamino-4-[3-(6-pyrrolidinonicotinoylamino)phenyl]quinazoline

[0201]



45

50

55

[0202] Starting from 167 mg of pyrrolidine, 183 mg of the title compound was obtained as yellow crystals in the same manner as in Example 30.


¹H-NMR (400MHz, CDCl₃)δ; 2.01-2.08(4H,m), 3.11(3H,d,J=5.0Hz), 3.47-3.57(4H,m), 3.87(3H,s), 4.02(3H,s), 5.16(1H,m), 6.39(1H,dd,J=8.9,0.6Hz), 7.07(1H,s), 7.22(1H,s), 7.46(1H,ddd,J=7.7,1.4,1.2Hz), 7.52(1H,dd,J=7.9,7.7Hz), 7.73-7.80(2H,m), 7.93-7.97(2H,m), 8.69(1H,dd,J=2.3,0.6Hz).

m.p.; 239-241°C

MASS 485 (MH⁺)

Example 32: 6,7-Dimethoxy-2-methylamino-4-[3-(6-methylaminonicotinoylamino)phenyl]quinazoline

[0203]



[0204] Starting from 5 ml solution of 40% methylamine in methanol, 162 mg of the title compound was obtained as yellow crystals in the same manner as in Example 30.


¹H-NMR (400MHz, CDCl₃)δ; 2.99(3H,d,J=5.2Hz), 3.12(3H,d,J=5.0Hz), 3.87(3H,s), 4.03(3H,s), 5.00(1H,m), 5.15(1H,m), 6.43(1H,dd,J=8.8,0.4Hz), 7.07(1H,s), 7.21(1H,s), 7.44-7.56(2H,m), 7.74-7.80(2H,m), 7.94-7.98(2H,m), 8.64(1H,dd,J=2.2,0.4Hz).

m.p.; 193-195°C

MASS 445 (MH⁺)

Example 33: 4-[3-(2-Chloroisonicotinoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0205]



[0206] Starting from 2-chloroisonicotinoyl chloride obtained by chlorinating 946 mg of 2-chloroisonicotinoic acid with thionyl chloride, 1.07 g of the title compound was obtained as pale yellow crystals in the same manner as in Exam-

ple 26.


¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.9Hz), 3.86(3H,s), 4.03(3H,s), 5.12(1H,m), 7.07(1H,s), 7.18(1H,s), 7.55-7.58(2H,m), 7.63(1H,dd,J=5.1,1.4Hz), 7.72-7.78(2H,m), 8.00(1H,dd,J=1.8,1.4Hz), 8.07(1H,br s), 8.56(1H,dd,J=5.1,0.7Hz).

m.p.; 151-153°C

MASS 450 (MH⁺)

Example 34: 6,7-Dimethoxy-2-methylamino-4-[3-(2-pyrrolidinonicotinoylamino)phenyl]quinazoline

[0207]



[0208] Starting from 225 mg of 4-[3-(2-chloroisonicotinoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline and 5 ml of pyrrolidine, 120 mg of the title compound was obtained as yellow crystals in the same manner as in Example 30.


¹H-NMR (400MHz, CDCl₃)δ; 2.00-2.07(4H,m), 3.11(3H,d,J=5.0Hz), 3.47-3.54(4H,m), 3.86(3H,s), 4.03(3H,s), 5.13(1H,m), 6.78(1H,dd,J=5.3,1.5Hz), 6.81(1H,dd,J=1.5,0.8Hz), 7.07(1H,s), 7.19(1H,s), 7.49-7.57(2H,m), 7.80(1H,ddd,J=7.7,2.0,1.4Hz), 7.96-8.00(2H,m), 8.27(1H,dd,J=5.3,0.8Hz).

m.p.; 135-137°C

MASS 485 (MH⁺)

Example 35: 4-(3-Benzenesulfonamidephenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0209]



[0210] Starting from benzenesulfonyl chloride, 295 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 1.


¹H-NMR (400MHz, CDCl₃)δ: 3.11(3H,d,J=4.8Hz), 3.79(3H,s), 4.02(3H,s), 5.43(1H,m), 6.95-7.02(2H,m), 7.05(1H,s), 7.26-7.31(2H,m), 7.39-7.47(3H,m), 7.54(1H,ddd,J=7.4,2.4,1.1Hz), 7.74(1H,br s), 7.78-7.82(2H,m).

m.p.; 230-232°C

MASS 451 (MH⁺)

Example 36: 6,7-Dimethoxy-2-methylamino-4-(3-(3-phenylureido)phenyl)quinazoline

[0211]



[0212] 310 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7 and 131 mg of benzene isocyanate were suspended in 20 ml tetrahydrofuran and stirred at room temperature for 1 hour. After ethyl acetate was added thereto, it was washed with water thrice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (ethyl acetate). The product was recrystallized from hexane-ethyl acetate-tetrahydrofuran to give 374 mg of the title compound as colorless crystals.


¹H-NMR (400MHz, CDCl₃)δ: 3.10(3H,d,J=4.9Hz), 3.83(3H,s), 4.01(3H,s), 5.16(1H,m), 6.81(1H,m), 6.90(1H,m), 7.06(1H,s), 7.10-7.16(2H,m), 7.31-7.40(5H,m), 7.45(1H,dd,J=8.6,7.7Hz), 7.56-7.60(2H,m).

m.p.; 218-220°C

MASS 430 (MH⁺)

Example 37: 6,7-Dimethoxy-2-methylamino-4-(3-phthalimide phenyl)quinazoline

[0213]



[0214] 155 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7 and 110 mg of N-carboethoxy phthalimide were suspended in 10 ml tetrahydrofuran and stirred at 60 °C for 18 hours. After 10 ml diisopropyl ether was added thereto, the resulting crystals were collected by filtration, washed with tetrahydrofuran-diisopropyl ether and then air-dried to give 191 mg of the title compound as yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ: 2.90(3H,d,J=5.0Hz), 3.84(3H,s), 3.93(3H,s), 7.01(1H,s), 7.10(1H,m), 7.22(1H,s), 7.66(1H,ddd,J=8.0,2.0,1.4Hz), 7.75(1H,dd,J=8.0,7.8Hz), 7.81(1H,ddd,J=7.8,1.4,1.4Hz), 7.85(1H,dd,J=2.0,1.4Hz), 7.90-7.95(2H,m), 7.97-8.02(2H,m).

m.p.: 280-282°C

MASS 441 (MH⁺)

Example 38: 4-(3-Benzylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0215]



[0216] 310 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7, 85.5 mg benzyl bromide and 138 mg potassium carbonate were suspended in 10 ml N,N-dimethyl formamide and stirred at room temperature for 2 hours. After ethyl acetate was added thereto, the mixture was washed with water 5 times and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:1). The product was recrystallized from hexane-ethyl acetate to give 110 mg of the title compound as pale yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ: 3.10(3H,d,J=5.0Hz), 3.76(3H,s), 4.02(3H,s), 4.22(1H,m), 4.38(2H,d,J=4.6Hz), 5.16(1H,m), 6.76(1H,ddd,J=8.2,2.4,0.8Hz), 6.95(1H,dd,J=2.4,1.6Hz), 7.00(1H,ddd,J=8.6,1.6,0.8Hz), 7.06(1H,s), 7.14(1H,s), 7.25-7.42(6H,m).

m.p.: 146-148°C

MASS 401 (MH⁺)

Example 39: 4-[3-(N-benzyl-N-methylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0217]




[0218] Starting from 100 mg of 4-(3-benzylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in

Example 38 and 71.0 mg of methyl iodide, 35.0 mg of the title compound was obtained as a pale yellow oil in the same manner as in Example 38.

¹H-NMR (400MHz, CDCl₃)δ; 3.07(3H,s), 3.11(3H,d,J=4.9Hz), 3.74(3H,s), 4.02(3H,s), 4.60(2H,s), 5.16(1H,m), 6.88(1H,ddd,J=8.4,2.4,0.5Hz), 7.00(1H,dd,J=8.2,0.5Hz), 7.04-7.07(2H,m), 7.16(1H,s), 7.21-7.37(6H,m).
MASS 415 (MH⁺)

Example 40: 4-[3-(N-benzyl-N-ethylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0219]




[0220] Starting from 78.0 mg of ethyl iodide, 28.0 mg of the title compound was obtained as a pale yellow oil in the same manner as in Example 39.

¹H-NMR (400MHz, CDCl₃)δ; 1.23(3H,t,J=7.0Hz), 3.09(3H,d,J=4.9Hz), 3.52(2H,q,J=7.0Hz), 3.75(3H,s), 4.02(3H,s), 4.58(2H,s), 5.12(1H,m), 6.88(1H,ddd,J=8.4,2.2,0.5Hz), 6.96(1H,dd,J=8.2,0.5Hz), 7.01(1H,dd,J=2.2,1.2Hz), 7.05(1H,s), 7.16(1H,s), 7.20-7.34(6H,m).
MASS 429 (MH⁺)

Example 41: 4-[3-(N-benzyl-N-propylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0221]



[0222] Starting from 200 mg of 4-(3-benzylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 38 and 170 mg of 1-iodopropyl, 66.0 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 38.


¹H-NMR (400MHz, CDCl₃)δ; 0.92(3H,t,J=7.4Hz), 1.71(2H,m), 3.09(3H,d,J=5.0Hz), 3.52(2H,t,J=7.3Hz), 3.74(3H,s), 4.01(3H,s), 4.61(2H,s), 5.12(1H,m), 6.78(1H,ddd,J=8.4,1.7,0.7Hz), 6.94(1H,dd,J=7.6,0.7Hz), 6.98(1H,dd,J=2.5,1.7Hz), 7.05(1H,s), 7.15(1H,s), 7.20-7.34(6H,m).

m.p.; 75-77°C

MASS 443 (MH⁺)

Example 42: 4-[3-(N-benzoyl-N-methylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline

[0223]



[0224] 207 mg of 4-(3-benzoylamino)phenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 1 was dissolved in 5 ml tetrahydrofuran, and 0.667 ml of 1.5 M lithium diisopropylamide in hexane was added dropwise thereto at -70 °C. After the dropwise addition, the mixture was stirred at -70 °C for 30 minutes, and then 284 mg of methyl iodide was added thereto. The mixture was returned to room temperature and further stirred for 1 hour. After ethyl acetate was added thereto, the mixture was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3). The product was recrystallized from hexane-ethyl acetate to give 75 mg of the title compound as pale yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ; 3.10(3H,d,J=5.0Hz), 3.55(3H,s), 3.78(3H,s), 4.02(3H,s), 5.11(1H,m), 6.90(1H,s), 7.06(1H,s), 7.13-7.28(4H,m), 7.35-7.40(3H,m), 7.46-7.50(2H,m).

m.p.; 198-200°C

MASS 429 (MH⁺)

Example 43: 6,7-Dimethoxy-9-methylamino-4-[3-(1-pyrrolyl)phenyl]quinazoline

[0225]



[0226] 310 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7

and 132 mg of 2,5-dimethoxy tetrahydrofuran were suspended in 1 ml acetic acid and heated under reflux for 15 minutes. After ethyl acetate was added thereto, the mixture was washed with aqueous saturated sodium bicarbonate thrice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:1). The product was recrystallized from hexane-ethyl acetate to give 179 mg of the title compound as yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ: 3.12(3H,d,J=5.0Hz), 3.82(3H,s), 4.04(3H,s), 5.17(1H,m), 6.38(2H,t,J=2.2Hz), 7.08(1H,s), 7.09(1H,s), 7.16(2H,t,J=2.2Hz), 7.53-7.61(3H,m), 7.74(1H,dd,J=1.8,1.4Hz).

m.p.: 199-201°C

MASS 361 (MH⁺)

Example 44: 6,7-Dimethoxy-4-[3-(2-isoindolynyl)phenyl]-2-methylaminoquinazoline

[0227]



[0228] 827 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7, 705 mg α,α'-dibromo-o-xylene and 738 mg potassium carbonate were dissolved in 30 ml N,N-dimethylformamide and stirred at 60 °C for 15 hours. After ethyl acetate was added thereto, the mixture was washed with water 5 times and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:1). The product was recrystallized from hexane-ethyl acetate to give 613 mg of the title compound as yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ: 3.13(3H,d,J=4.7Hz), 3.82(3H,s), 4.03(3H,s), 4.72(4H,s), 5.16(1H,m), 6.82(1H,ddd,J=8.2,2.4,0.8Hz), 6.97(1H,dd,J=2.4,1.6Hz), 7.04(1H,ddd,J=7.6,1.6,0.8Hz), 7.09(1H,s), 7.25(1H,s), 7.29-7.38(4H,m), 7.44(1H,dd,J=7.6,8.2Hz).

m.p.: 194-196°C

MASS 413 (MH⁺)

Example 45: 6,7-Dimethoxy-4-[3-(1-oxo-2-isoindolynyl)phenyl]-2-methylaminoquinazoline

[0229]




20 [0230] 155 mg of 4-(3-aminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 7, 67 mg phthalic carbaldehyde and 5 mg acetic acid were dissolved in 1 ml chloroform and stirred at 50 °C for 1 hour. After ethyl acetate was added thereto, the mixture was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:3). The product was recrystallized from hexane-ethyl acetate to give 50.0 mg of the title compound as yellow crystals.

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.0Hz), 3.87(3H,s), 4.04(3H,s), 4.93(2H,s), 5.18(1H,m), 7.08(1H,s), 7.24(1H,s), 7.49-7.57(3H,m), 7.58-7.64(2H,m), 7.94(1H,ddd,J=7.4,2.0,1.0Hz), 8.06(1H,ddd,J=8.2,2.4,1.0Hz), 7.97(1H,dd,J=2.0,1.4Hz).

30 m.p.; 230-232°C
MASS 427 (MH⁺)

Example 46: 4-(3-Biphenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0231]




50 [0232] Starting from 90 mg of 4-(3-biphenyl)-2-chloro-6,7-dimethoxyquinazoline obtained in Production Example 2 and 10 ml solution of 40% methylamine in methanol, 808 mg of the title compound was obtained as a pale yellow crystals in the same manner as in Production Example 8.

55 ¹H-NMR (400MHz, CDCl₃)δ; 3.14(3H,d,J=4.8Hz), 3.82(3H,s), 4.04(3H,s), 4.58(1H,br s), 7.09(1H,s), 7.15(1H,s), 7.37(1H,m), 7.46(2H,m), 7.60(1H,t,J=7.6Hz), 7.65(2H,m), 7.67(1H,dt,J=7.6,1.6Hz), 7.75(1H,dt,J=7.6,1.6Hz), 7.93(1H,t,J=1.6Hz).

m.p.; 183-185°C

MASS 372 (MH⁺)Example 47: 6,7-Dimethoxy-2-methylamino-4-[3-(3-pyridyl)phenyl]quinazoline

[0233]




[0234] 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8, 150 mg of 3-pyridyl diethyl borane, 50 mg of tetrakis(triphenyl phosphine) palladium, 50 mg of tetrabutyl ammonium bromide and 120 mg potassium hydroxide were suspended in 10 ml tetrahydrofuran and heated under reflux for 4 hours. After ethyl acetate was added thereto, the mixture was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (dichloromethane:methanol=30:1). The product was recrystallized from hexane-chloroform to give 210 mg of the title compound as pale yellow crystals.

¹H-NMR (400MHz, CDCl₃)δ; 3.14(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.13(1H,br s), 7.10(1H,s), 7.11(1H,s), 7.39(1H,m), 7.65(1H,t,J=7.6Hz), 7.72-7.76(2H,m), 7.92-7.95(2H,m), 8.62(1H,dd,J=4.8,1.6Hz), 8.92(1H,dd,J=2.4,0.8Hz).

m.p.; 186-188°C

MASS 373 (MH⁺)Example 48: 6,7-Dimethoxy-4-(3',4'-dimethyl-3-biphenyl)-2-methylaminoquinazoline

[0235]



[0236] 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8, 200 mg of 1,2-dimethyl-4-phenyl boric acid obtained from 4-bromo-o-xylene according to the method of J. Org. Chem., 56, 3763 (1991) and 50 mg tetrakis(triphenyl phosphine)palladium were suspended in a mixed solvent of 20 ml toluene, 5 ml methanol and 10 ml of 2 M aqueous sodium carbonate, and the mixture was stirred at 80 °C for 8 hours. The

organic layer was recovered, washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=1:1). The product was recrystallized from hexane-diisopropyl ether to give 186 mg of the title compound as pale yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ; 2.31(3H,s), 2.33(3H,s), 3.14(3H,d,J=4.8Hz), 3.82(3H,s), 4.04(3H,s), 5.14(1H,br s), 7.09(1H,s), 7.16(1H,s), 7.22(1H,m), 7.39(1H,m), 7.43(1H,m), 7.58(1H,t,J=7.6Hz), 7.63(1H,dt,J=7.6,1.6Hz), 7.73(1H,dt,J=7.6,1.6Hz), 7.90(1H,t,J=1.6Hz).

m.p.; 149-151°C

MASS 400 (MH⁺)

Example 49: 6,7-Dimethoxy-2-methylamino-4-[3-(3-quinolyl)phenyl]quinazoline

[0237]



[0238] 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8, 300 mg of 3-quinolyl diethyl borane obtained from 4-bromoquinoline according to the method of Heterocycles, 22, 2471 (1984), 50 mg tetrakis(triphenyl phosphine)palladium, 50 mg tetrabutyl ammonium bromide and 120 mg potassium hydroxide were suspended in 10 ml tetrahydrofuran, and the mixture was heated under reflux for 6 hours. After ethyl, acetate was added thereto, the mixture was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (ethyl acetate:methanol=30:1). The product was recrystallized from hexane-chloroform to give 236 mg of the title compound as pale yellow crystals.


¹H-NMR (400MHz, CDCl₃)δ; 3.15(3H,d,J=4.8Hz), 3.83(3H,s), 4.05(3H,s), 5.16(1H,br s), 7.11(1H,s), 7.15(1H,s), 7.60(1H,m), 7.70(1H,t,J=8.0Hz), 7.73-7.78(2H,m), 7.87-7.90(2H,m), 8.06(1H,t,J=1.6Hz), 8.16(1H,d,J=8.0Hz), 8.38(1H,d,J=2.4Hz), 9.25(1H,d,J=2.4Hz).

m.p.; 218-220°C

MASS 423 (MH⁺)

Example 50: 6,7-Dimethoxy-4-[3-(imidazo[1,2-a]pyridine-6-yl)phenyl]-2-methylaminoquinazoline

[0239]




[0240] Starting from 250 mg of imidazo[1,2-a]pyridin-6-yl diethyl borane obtained from 6-bromoimidazo[1,2-a]pyridine according to the method of *Heterocycles*, 22, 2471, 1984., 176 mg of the title compound was obtained as yellow crystals in the same manner as in Example 49.

¹H-NMR (400MHz, CDCl₃)δ: 3.14(3H,d,J=4.8Hz), 3.82(3H,s), 4.04(3H,s), 5.15(1H,br s), 7.10(2H,s), 7.49(1H,dd,J=5.4,1.8Hz), 7.62-7.74(6H,m), 7.91(1H,t,J=1.8Hz), 8.40(1H,dd,J=1.6,0.8Hz).
m.p.; 237-239°C
MASS 412 (MH⁺)

Example 51: 6,7-Dimethoxy-2-methylamino-4-[3-(4-isoquinolyl)phenyl]quinazoline

[0241]




[0242] Starting from 250 mg of 4-isoquinolyl diethyl borane obtained from 4-bromoisoquinoline according to the method of *Heterocycles*, 22, 2471, 1984., 147 mg of the title compound was obtained as yellow crystals in the same manner as in Example 49.

¹H-NMR (400MHz, CDCl₃)δ: 3.13(3H,d,J=4.8Hz), 3.85(3H,s), 4.03(3H,s), 5.13(1H,br s), 7.09(1H,s), 7.20(1H,s), 7.63-7.73(4H,m), 7.83(1H,m), 7.88(1H,m), 7.98(1H,m), 8.07(1H,m), 8.56(1H,s), 9.29(1H,s).
m.p.; 181-183°C
MASS 423 (MH⁺)

Example 52: 6,7-Dimethoxy-2-methylamino-4-(4'-methylthio-3-biphenyl)quinazoline

[0243]



[0244] Starting from 450 mg of 4-methylthiophenylboric acid obtained from 750 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8 and 4-bromothioanisole according to the method of *J. Org. Chem.*, 56, 3763, 1991., 523 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 48.


¹H-NMR (400MHz, CDCl₃)δ; 2.53(3H,s), 3.14(3H,d,J=4.8Hz), 3.81(3H,s), 4.04(3H,s), 5.14(1H,br s), 7.09(1H,s), 7.13(1H,s), 7.34(2H,d,J=8.8Hz), 7.58(2H,d,J=8.8Hz), 7.60(1H,t,J=7.6Hz), 7.65(1H,dt,J=7.6,1.6Hz), 7.72(1H,dt,J=7.6,1.6Hz), 7.90(1H,t,J=1.6Hz).

m.p.; 140-142°C

MASS 418 (MH⁺)

Example 53: 6,7-Dimethoxy-2-methylamino-4-(4'-methylsulfinyl-3-biphenyl)quinazoline

[0245]



[0246] Starting from 250 mg of 6,7-dimethoxy-2-methylamino-4-(4'-methylthio-3-biphenyl)quinazoline obtained in Example 52, 139 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 27.


¹H-NMR (400MHz, CDCl₃)δ; 2.78(3H,s), 3.13(3H,d,J=4.8Hz), 3.81(3H,s), 4.04(3H,s), 5.17(1H,br s), 7.10(1H,s), 7.11(1H,s), 7.64(1H,t,J=7.6Hz), 7.72(1H,dt,J=7.6,1.6Hz), 7.74(2H,d,J=8.4Hz), 7.76(1H,dt,J=7.6,1.6Hz), 7.81(2H,d,J=8.8Hz), 7.94(1H,t,J=1.6Hz).

m.p.; 153-155°C

MASS 434 (MH⁺)

Example 54: 6,7-Dimethoxy-9-methylamino-4-(3'-methylthio-3-biphenyl)quinazoline

[0247]




[0248] Starting from 450 mg of 3-methylthiophenylboric acid obtained from 3-bromothiobanisole according to the method of *J. Org. Chem.*, **56**, 3763, 1991., 485 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 52.

¹H-NMR (400MHz, CDCl₃)δ; 2.53(3H,s), 3.14(3H,d,J=4.8Hz), 3.82(3H,s), 4.04(3H,s), 5.15(1H,br s), 7.09(1H,s), 7.13(1H,s), 7.27(1H,dt,J=7.6,1.6Hz), 7.38(1H,t,J=7.6Hz), 7.41(1H,dt,J=7.6,1.6Hz), 7.53(1H,t,J=1.6Hz), 7.60(1H,t,J=7.6Hz), 7.68(1H,dt,J=7.6,1.6Hz), 7.73(1H,dt,J=7.6,1.6Hz), 7.90(1H,t,J=1.6Hz).
m.p.; 195-197°C
MASS 418 (MH⁺)

Example 55: 6,7-Dimethoxy-2-methylamino-4-(3'-methylsulfinyl-3-biphenyl)quinazoline

[0249]




[0250] Starting from 250 mg of 6,7-dimethoxy-2-methylamino-4-(3'-methylthio-3-biphenyl)quinazoline obtained in Example 54, 145 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 27.

¹H-NMR (400MHz, CDCl₃)δ; 2.78(3H,s), 3.14(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.15(1H,br s), 7.09(1H,s), 7.10(1H,s), 7.61-7.65(3H,m), 7.71(1H,dt,J=7.6,1.6Hz), 7.77-7.80(2H,m), 7.95-7.97(2H,m).
m.p.; 163-165°C
MASS 434 (MH⁺)

Example 56: 6,7-Dimethoxy-2-methylamino-4-(3'-phenyl-3-biphenyl)quinazoline

[0251]




[0252] Starting from 200 mg of 3-biphenylboric acid, 202 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 48.

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.16(1H,br s), 7.10(1H,s), 7.17(1H,s), 7.37(1H,m), 7.43-7.48(2H,m), 7.53(1H,t,J=7.6Hz), 7.59-7.65(5H,m), 7.69(1H,dt,J=7.6,1.6Hz), 7.81(1H,dt,J=7.6,1.6Hz), 7.86(1H,t,J=1.6Hz), 7.98(1H,t,J=1.6Hz).
m.p.; 193-195°C
MASS 448 (MH⁺)

Example 57: 6,7-Dimethoxy-4-[3-(5-methoxy-3-pyridyl)phenyl]-2-methylaminoquinazoline

[0253]




[0254] Starting from 250 mg of 3-methoxypyridin-5-yl diethyl borane obtained from 3-bromo-5-methoxypyridine according to the method of *Heterocycles*, 22, 2471, 1984., 206 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 49.

¹H-NMR (400MHz, CDCl₃)δ; 3.14(3H,d,J=4.8Hz), 3.82(3H,s), 3.92(3H,s), 4.04(3H,s), 5.14(1H,br s), 7.10(1H,s), 7.11(1H,s), 7.42(1H,dd,J=2.8,1.8Hz), 7.64(1H,t,J=7.6Hz), 7.71-7.75(2H,m), 7.91(1H,t,J=1.6Hz), 8.33(1H,d,J=2.8Hz), 8.52(1H,d,J=1.8Hz).
m.p.; 225-227°C
MASS 403 (MH⁺)

Example 58: 6,7-Dimethoxy-2-methylamino-4-[3-(5-methylthio-3-pyridyl)phenyl]quinazoline

[0255]




[0256] Starting from 550 mg of 3-methylthiopyridin-5-yl diethyl borane obtained from 3-bromo-5-methylthiopyridine according to the method of *Heterocycles*, 22, 2471, 1984., 440 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 52.

¹H-NMR (400MHz, CDCl₃)δ; 2.56(3H,s), 3.14(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.15(1H,br s), 7.10(2H,s), 7.65(1H,t,J=7.6Hz), 7.71-7.75(2H,m), 7.79(1H,t,J=2.2Hz), 7.90(1H,t,J=1.6Hz), 8.50(1H,d,J=2.2Hz), 8.66(1H,d,J=2.2Hz).
m.p.; 184-186°C
MASS 419 (MH⁺)

Example 59: 6,7-Dimethoxy-2-methylamino-4-[3-(5-methylsulfinyl-3-pyridyl)phenyl]quinazoline

[0257]




[0258] Starting from 250 mg of 6,7-dimethoxy-2-methylamino-4-[3-(5-methylthio-3-pyridyl)phenyl]quinazoline obtained in Example 58, 124 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 27.

¹H-NMR (400MHz, CDCl₃)δ; 2.86(3H,s), 3.14(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.16(1H,br s), 7.08(1H,s), 7.10(1H,s), 7.68(1H,t,J=7.6Hz), 7.77-7.82(2H,m), 7.98(1H,t,J=1.6Hz), 8.35(1H,t,J=2.0Hz), 8.75(1H,d,J=2.0Hz), 9.03(1H,d,J=2.0Hz).
m.p.; 208-210°C
MASS 435 (MH⁺)

Example 60: 6,7-Diethoxy-2-methylamino-4-[3-(3-quinolyl)phenyl]quinazoline

[0259]



[0260] Starting from 250 mg of 4-(3-bromophenyl)-6,7-diethoxy-2-methylaminoquinazoline obtained in Production Example 15 and 200 mg of 3-quinolyl diethyl borane, 121 mg of the title compound was obtained as yellow crystals in the same manner as in Example 49.


m.p.; 157-159°C

MASS 451 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ: 1.43(3H,t,J=7.2Hz), 1.55(3H,t,J=7.2Hz), 3.14(3H,d,J=5.2Hz), 4.00(2H,q,J=7.2Hz), 4.27(2H,q,J=7.2Hz), 5.12(1H,br s), 7.08(1H,s), 7.15(1H,s), 7.60(1H,m), 7.71(1H,t,J=8.0Hz), 7.73-7.78(2H,m), 7.86-7.91(2H,m), 8.05(1H,t,J=1.6Hz), 8.15(1H,d,J=8.4Hz), 8.38(1H,d,J=2.4Hz), 9.25(1H,d,J=2.4Hz).

Example 61: 6,7-Diethoxy-2-methylamino-4-[3-(5-methylthio-3-pyridyl)phenyl]quinazoline

[0261]



[0262] Starting from 1.00 g of 4-(3-bromophenyl)-6,7-diethoxy-2-methylaminoquinazoline obtained in Production Example 15 and 700 mg of 3-methylthiopyridin-5-yl diethyl borane, 472 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 49.

m.p.; 105-107°C


MASS 447 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ: 1.43(3H,t,J=7.2Hz), 1.55(3H,t,J=7.2Hz), 2.56(3H,s), 3.13(3H,d,J=4.8Hz), 4.00(2H,q,J=7.2Hz), 4.27(2H,q,J=7.2Hz), 5.12(1H,br s), 7.07(1H,s), 7.12(1H,s), 7.64(1H,t,J=7.6Hz), 7.70-

7.75(2H,m), 7.78(1H,t,J=2.2Hz), 7.89(1H,t,J=1.8Hz), 8.50(1H,d,J=2.2Hz), 8.66(1H,d,J=2.2Hz).

Example 62: 6,7-Diethoxy-2-methylamino-4-[3-(5-methylsulfinyl-3-pyridyl)phenyl]quinazoline

[0263]



[0264] Starting from 360 mg of 6,7-diethoxy-2-methylamino-4-[3-(5-methylthio-3-pyridyl)phenyl]quinazoline obtained in Example 61, 84 mg of the title compound was obtained as yellow crystals in the same manner as in Example 27.


m.p.; 188-190°C

MASS 463 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 1.43(3H,t,J=7.2Hz), 1.56(3H,t,J=7.2Hz), 2.86(3H,s), 3.13(3H,d,J=5.2Hz), 4.00(2H,q,J=7.2Hz), 4.26(2H,q,J=7.2Hz), 5.17(1H,br s), 7.07(1H,s), 7.09(1H,s), 7.68(1H,t,J=7.6Hz), 7.74-7.81(2H,m), 7.97(1H,t,J=1.6Hz), 8.34(1H,t,J=2.0Hz), 8.75(1H,d,J=2.0Hz), 9.03(1H,d,J=2.0Hz).

Example 63: 6,7-Dimethoxy-2-methylamino-4-[3-(5-phenyl-3-pyridyl)phenyl]quinazoline

[0265]



[0266] Starting from 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8 and 250 mg of 5-phenyl-3-pyridyl diethyl borane, 190 mg of the title compound was obtained as yellow crystals in the same manner as in Example 49.


m.p.; 200-202°C

MASS 449 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.14(3H,d,J=5.2Hz), 3.82(3H,s), 4.04(3H,s), 5.16(1H,br s), 7.10(1H,s), 7.13(1H,s), 7.44(1H,m), 7.47-7.53(2H,m), 7.62-7.70(3H,m), 7.75(1H,m), 7.81(1H,m), 7.98(1H,t,J=1.4Hz), 8.11(1H,t,J=2.0Hz), 8.85(1H,d,J=2.0Hz), 8.89(1H,d,J=2.0Hz).

5 Example 64: 6,7-Dimethoxy-4-[3-(8-methyl-3-quinolyl)phenyl]-2-methylaminoquinazoline

[0267]



25 **[0268]** Starting from 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8 and 220 mg of 8-methyl-3-quinolyl diethyl borane, 110 mg of the title compound was obtained as yellow crystals in the same manner as in Example 49.


30 m.p.; 188-190°C

MASS 437 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 2.86(3H,s), 3.15(3H,d,J=4.8Hz), 3.83(3H,s), 4.05(3H,s), 5.17(1H,br s), 7.11(1H,s), 7.16(1H,s), 7.48(1H,dd,J=8.0,7.2Hz), 7.60(1H,m), 7.68-7.78(3H,m), 7.89(1H,m), 8.07(1H,t,J=1.6Hz), 8.35(1H,d,J=1.6Hz), 9.27(1H,d,J=1.6Hz).

35 Example 65: 6,7-Dimethoxy-2-methylamino-4-[3-(2-phenyl ethynyl)phenyl]quinazoline

[0269]



55 **[0270]** 374 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8, 153 mg of phenyl acetylene, 70.2 mg of bis(triphenyl phosphine)palladium dichloride, 19.0 mg copper iodide and 202 mg triethylamine were suspended in 10 ml N,N-dimethylformamide and heated under reflux for 6 hours. After ethyl ace-

tate was added thereto, the mixture was washed with water twice and with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, and the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=2:1). The product was recrystallized from hexane-ethanol to give 111 mg of the title compound as pale yellow crystals.


m.p.; 102-104°C

MASS 396 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ: 3.13(3H,d,J=5.0Hz), 3.83(3H,s), 4.04(3H,s), 5.15(1H,br s), 7.06(1H,s), 7.08(1H,s), 7.33-7.40(3H,m), 7.50-7.57(3H,m), 7.64(1H,dt,J=7.7,1.6Hz), 7.68(1H,dt,J=7.7,1.6Hz), 7.87(1H,t,J=1.6Hz).

Example 66: 6,7-Dimethoxy-2-methylamino-4-[3-(2-phenylethyl)phenyl]quinazoline

[0271]



[0272] 70.0 mg of 6,7-dimethoxy-2-methylamino-4-[3-(2-phenyl ethynyl)phenyl]quinazoline obtained in Example 65, 50.0 mg Lindlar catalyst and 50.0 mg triethylamine were suspended in a mixed solvent of 5 ml ethanol and 5 ml tetrahydrofuran. After the atmosphere was replaced with hydrogen, the mixture was stirred for 6 hours at ordinary pressure at room temperature. The reaction solution was filtered, and the filtrate was evaporated. Then, the crude product was purified and separated by silica gel column chromatography (hexane:ethyl acetate=2:1). The product was recrystallized from hexane-isopropanol to give 45.0 mg of the title compound as colorless crystals.


m.p.; 95-97°C

MASS 400 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ: 2.95-3.06(4H,m), 3.13(3H,d,J=4.9Hz), 3.80(3H,s), 4.03(3H,s), 5.17(1H,br s), 7.08(1H,s), 7.09(1H,s), 7.17-7.24(3H,m), 7.25-7.36(3H,m), 7.45(1H,t,J=7.5Hz), 7.51-7.58(2H,m).

Example 67: 6,7-Dimethoxy-2-methylamino-4-[3-[2-(3-pyridyl)ethynyl]phenyl]quinazoline

[0273]



[0274] Starting from 374 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8 and 163 mg of 3-pyridylacetylene obtained from 3-bromopyridine, 35 mg of the title compound was obtained as yellow crystals in the same manner as in Example 65.


m.p.; 103-105°C

MASS 397 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=4.9Hz), 3.83(3H,s), 4.04(3H,s), 5.17(1H,br s), 7.05(1H,s), 7.09(1H,s), 7.30(1H,ddd,J=8.0,5.0,1.0Hz), 7.55(1H,t,J=8.0Hz), 7.66-7.72(2H,m), 7.82(1H,dt,J=8.0,2.0Hz), 7.89(1H,t,J=2.0Hz), 8.56(1H,dd,J=5.0,2.0Hz), 8.78(1H,dd,J=2.0,1.0Hz).

Example 68: 6,7-Dimethoxy-2-methylamino-4-[3-[2-(6-methylamino-3-pyridyl)ethynyl]phenyl]quinazoline

[0275]



[0276] Starting from 250 mg of 4-(3-bromophenyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Production Example 8 and 166 mg of 6-methylamino-3-pyridylacetylene obtained from 2,5-dibromopyridine, 68 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 65.


m.p.; 136-138°C

MASS 426 (MH⁺)

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ : 2.95(3H,d,J=5.1Hz), 3.13(3H,d,J=4.9Hz), 3.82(3H,s), 4.03(3H,s), 4.74(1H,br s), 5.15(1H,br s), 6.36(1H,dd,J=8.6,0.4Hz), 7.06(1H,s), 7.08(1H,s), 7.50(1H,t,7.8Hz), 7.56(1H,dd,J=8.6,2.0Hz), 7.60-7.66(2H,m), 7.83(1H,t,J=1.6Hz), 8.29(1H,d,J=2.0Hz).

5 **Example 69: 6,7-Dimethoxy-2-methylamino-4-[3-(2-methylaminoquinazoline**

[0277]



[0278] 6,7-Dimethoxy-4-(3-formylphenyl)-2-methylaminoquinazoline (323 mg) obtained in Production Example 18 was subjected in a usual manner to Wittig-Horner reaction with diethyl benzyl phosphonate to give 145 mg of the title compound was obtained as pale yellow crystals.


m.p.; 110-112°C

MASS 398 (MH^+)

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ : 3.14(3H,d,J=4.9Hz), 3.81(3H,s), 4.04(3H,s), 5.17(1H,br s), 7.09(1H,s), 7.11(1H,s), 7.19(2H,s), 7.28(1H,m), 7.34-7.40(2H,m), 7.50-7.60(4H,m), 7.66(1H,dt,J=7.5,1.5Hz), 7.85(1H,t,J=1.5Hz).

Example 70: 6,7-Dimethoxy-2-methylamino-4-(3-phenylcarbamoylphenyl)quinazoline

[0279]



[0280] 2-Chloro-4-(3-chloroformylphenyl)-6,7-dimethoxyquinazoline (310 mg) obtained in Production Example 17 was reacted with aniline in a conventional manner, and then treated in the same manner as in Example 46 to give 226 mg of the title compound as pale yellow crystals.

m.p.; 242-244°C


MASS 415 (MH^+)

$^1\text{H-NMR}$ (400MHz, CDCl_3) δ : 3.13(3H,d,J=4.8Hz), 3.81(3H,s), 4.03(3H,s), 5.16(1H,br s), 7.00(1H,s), 7.08(1H,s),

7.17(1H,m), 7.36-7.42(2H,m), 7.64-7.70(3H,m), 7.87(1H,m), 7.98(1H,br s), 8.04(1H,m), 8.19(1H,t,J=1.6Hz).

Example 71: 6,7-Dimethoxy-2-methylamino-4-[3-(3-pyridyl)carbamolphenyl]quinazoline

[0281]



[0282] 2-Chloro-4-(3-chloroformylphenyl)-6,7-dimethoxyquinazoline (310 mg) obtained in Production Example 17 was reacted with 3-aminopyridine in a conventional manner, and then treated in the same manner as in Example 46 to give 182 mg of the title compound as pale yellow crystals.


m.p.; 238-240°C

MASS 416 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.2Hz), 3.79(3H,s), 4.02(3H,s), 5.17(1H,br s), 6.97(1H,s), 7.06(1H,s), 7.34(1H,dd,J=8.4,4.4Hz), 7.68(1H,t,J=8.0Hz), 7.88(1H,m), 8.08(1H,m), 8.20-8.26(2H,m), 8.33(1H,m), 8.41(1H,dd,J=4.4,2.0Hz), 8.72(1H,d,J=2.0Hz).

Example 72: 4-(3-Benzoyloxyphenyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0283]



[0284] Starting from 500 mg of 2-chloro-6,7-dimethoxy-4-(3-benzyloxyphenyl)quinazoline obtained from 3,4-dichloro-6,7-dimethoxyquinazoline and 3-benzyloxyphenyl boric acid in the same manner as in Production Example 1, 391 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 46.


m.p.; 116-118°C

MASS 402 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=4.8Hz), 3.78(3H,s), 4.03(3H,s), 5.13(2H,s), 7.07(1H,s), 7.09(1H,s), 7.13(1H,dd,J=6.8,0.8Hz), 7.27(1H,m), 7.31-7.46(7H,m).

Example 73: 6,7-Dimethoxy-2-methylamino-4-(3-phenoxyphenyl)quinazoline

[0285]



[0286] Starting from 250 mg of 2-chloro-6,7-dimethoxy-4-(3-phenoxyphenyl)quinazoline obtained from 3,4-dichloro-6,7-dimethoxyquinazoline and 3-phenoxyphenyl boric acid in the same manner as in Production Example 1, 146 mg of the title compound was obtained as yellow crystals in the same manner as in Example 46.


m.p.; 157-159°C

MASS 388 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.8Hz), 3.79(3H,s), 4.02(3H,s), 4.12(1H,br s), 7.05(1H,s), 7.06(1H,s), 7.08(2H,m), 7.12(1H,m), 7.17(1H,m), 7.32-7.37(3H,m), 7.43(1H,dt,J=7.6,1.2Hz), 7.50(1H,t,J=7.6Hz).

Example 74: 6,7-Dimethoxy-2-methylamino-4-(5-phenyl-2-thienyl)quinazoline

[0287]



[0288] Starting from 286 mg of 2-chloro-6,7-dimethoxy-4-(5-phenyl-2-thienyl)quinazoline obtained from 3,4-dichloro-6,7-dimethoxyquinazoline and 5-phenyl-2-thienylboric acid in the same manner as in Production Example 1, 180 mg of the title compound was obtained as yellow crystals in the same manner as in Example 46.


m.p.; 201-203°C

MASS 378 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.0Hz), 3.97(3H,s), 4.03(3H,s), 5.09(1H,br s), 7.05(1H,s), 7.35(1H,m), 7.40-7.46(3H,m), 7.58(1H,s), 7.68-7.74(3H,m).

Example 75: 6,7-Dimethoxy-2-methylamino-4-(5-phenyl-3-pyridyl)quinazoline

[0289]



[0290] Starting from 445 mg of 2-chloro-6,7-dimethoxy-4-(5-phenyl-3-pyridyl)quinazoline obtained from 3,4-dichloro-6,7-dimethoxyquinazoline and 5-phenyl-3-pyridylboric acid in the same manner as in Production Example 1, 220 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 46.


m.p.; 177-179°C

MASS 373 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.11(3H,d,J=4.9Hz), 3.84(3H,s), 4.05(3H,s), 5.16(1H,br s), 7.07(1H,s), 7.10(1H,s), 7.45(1H,m), 7.49-7.54(2H,m), 7.65-7.69(2H,m), 8.24(1H,t,J=2.0Hz), 8.93(1H,d,J=2.0Hz), 9.00(1H,d,J=2.0Hz).

Example 76: 4-(5-Bromo-3-pyridyl)-6,7-dimethoxy-2-methylaminoquinazoline

[0291]



[0292] Starting from 2.40 g of 2-chloro-6,7-dimethoxy-4-(5-bromo-3-pyridyl)quinazoline obtained from 3,4-dichloro-6,7-dimethoxyquinazoline and 5-bromo-3-pyridylboric acid in the same manner as in Production Example 1, 1.46 g of the title compound was obtained as pale yellow crystals in the same manner as in Example 46.


m.p.; 228-230°C

MASS 375, 377 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.12(3H,d,J=5.0Hz), 3.85(3H,s), 4.04(3H,s), 5.15(1H,br s), 6.96(1H,s), 7.07(1H,s), 8.21(1H,t,J=2.0Hz), 8.83(1H,d,J=2.0Hz), 8.88(1H,d,J=2.0Hz).

Example 77: 6,7-Dimethoxy-2-methylamino-4-[5-(4-methylthiophenyl)-3-pyridyl]quinazoline

[0293]



[0294] Starting from 375 mg of 4-(5-bromo-3-pyridyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 76 and 225 mg of 4-methylthiophenylboric acid, 440 mg of the title compound was obtained as pale yellow crystals in the same manner as in Example 48.


m.p.; 170-172°C

MASS 419 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 2.54(3H,s), 3.13(3H,d,J=5.0Hz), 3.84(3H,s), 4.04(3H,s), 5.18(1H,br s), 7.06(1H,s), 7.10(1H,s), 7.35-7.40(2H,m), 7.57-7.62(2H,m), 8.21(1H,t,J=2.0Hz), 8.91(1H,d,J=2.0Hz), 8.97(1H,d,J=2.0Hz).

Example 78: 6,7-Dimethoxy-2-methylamino-4-[5-[2-(3-pyridyl)ethynyl]-3-pyridyl]quinazoline

[0295]



[0296] Starting from 250 mg of 4-(5-bromo-3-pyridyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 76 and 195 mg of 3-pyridylacetylene obtained from 3-bromopyridine, 184 mg of the title compound was obtained as yellow crystals in the same manner as in Example 71.

m.p.; 208-211°C


MASS 398 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.0Hz), 3.85(3H,s), 4.05(3H,s), 5.17(1H,br s), 6.99(1H,s), 7.09(1H,s),

7.33(1H,ddd,J=8.0,5.0,1.0Hz), 7.85(1H,dt,J=8.0,2.0Hz), 8.20(1H,t,J=2.0Hz), 8.61(1H,dd,J=5.0,2.0Hz), 8.81(1H,dd,J=2.0,1.0Hz), 8.91(2H,d,J=2.0Hz).

Example 79: 6,7-Dimethoxy-2-methylamino-4-[5-[2-(6-methylamino-3-pyridyl)ethynyl]-3-pyridyl]quinazoline

[0297]



[0298] Starting from 250 mg of 4-(5-bromo-3-pyridyl)-6,7-dimethoxy-2-methylaminoquinazoline obtained in Example 76 and 166 mg of 6-methylamino-3-pyridylacetylene obtained from 2,5-dibromopyridine, 215 mg of the title compound was obtained as yellow crystals in the same manner as in Example 65.


m.p.; 160-162°C

MASS 427 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 2.97(3H,d,J=5.4Hz), 3.13(3H,d,J=4.9Hz), 3.85(3H,s), 4.04(3H,s), 4.82(1H,br s), 5.17(1H,br s), 6.38(1H,dd,J=8.6,0.6Hz), 6.99(1H,s), 7.09(1H,s), 7.58(1H,dd,J=8.6,2.2Hz), 8.12(1H,t,J=2.0Hz), 8.31(1H,dd,J=2.2,0.6Hz), 8.83(1H,d,J=2.0Hz), 8.85(1H,d,J=2.0Hz).

Example 80: 4-(3-Aminophenyl)-6-benzyloxy-7-methoxy-2-methylaminoquinazoline

[0299]




[0300] Starting from 289 mg of 4-(3-aminophenyl)-6-benzyloxy-2-chloro-7-methoxyquinazoline obtained from 6-benzyloxy-2,4-dichloro-7-methoxyquinazoline obtained in Production Example 19 and 3-aminophenyl boric acid in the same manner as in Production Example 1, 295 mg of the title compound was obtained as yellow crystals in the same manner as in Example 46.

MASS 387 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.10(3H,d,J=5.0Hz), 3.72(2H,m), 4.03(3H,s), 5.06-5.14(3H,m), 6.78-6.84(3H,m), 7.06(1H,s), 7.14(1H,s), 7.21(1H,t,J=7.8Hz), 7.28-7.40(5H,m).

5 Example 81: 4-(3-Benzoylamino-phenyl)-6-benzyloxy-7-methoxy-2-methylaminoquinazoline

[0301]



[0302] 4-(3-Aminophenyl)-6-benzyloxy-7-methoxy-2-methylaminoquinazoline (248 mg) obtained in Example 80 was benzoylated in a conventional manner to give 298 mg of the title compound as pale yellow crystals.


m.p.; 204-206°C

MASS 491 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ; 3.13(3H,d,J=5.0Hz), 4.04(3H,s), 5.11(1H,br s), 5.15(2H,s), 7.08(1H,s), 7.18(1H,s), 7.20-7.25(2H,m), 7.29-7.34(2H,m), 7.36-7.41(2H,m), 7.43-7.61(4H,m), 7.78(1H,m), 7.85-7.93(4H,m).

Example 82: 4-(3-Benzoylamino-phenyl)-6-hydroxy-7-methoxy-2-methylaminoquinazoline

[0303]



[0304] 4-(3-Benzoylamino-phenyl)-6-benzyloxy-7-methoxy-2-methylaminoquinazoline (245 mg) obtained in Example 81 was catalytically reduced in a conventional manner to give 166 mg of the title compound as pale yellow crystals.


m.p.; 145-147°C

MASS 401 (MH⁺)

¹H-NMR (400 MHz, CDCl₃)δ; 3.09(3H,d,J=5.1Hz), 4.01(3H,s), 5.18(1H,br s), 7.06(1H,s), 7.24(1H,s), 7.39(1H,m), 7.42-7.50(3H,m), 7.54(1H,m), 7.82-7.92(4H,m), 8.11(1H,br s).

Example 83: 2-Amino-4-(3-biphenyl)-6,7-dimethoxyquinoline

[0305]




[0306] Starting from 180 mg of 2-amino-4-(3-bromophenyl)-6,7-dimethoxyquinoline obtained in Production Example 20 and 91.4 mg of phenyl boric acid, 168 mg of the title compound was obtained as a pale yellow oil in the same manner as in Example 48.

MASS 357 (MH⁺)

¹H-NMR (400 MHz, CDCl₃)δ: 3.79(3H,s), 4.01(3H,s), 4.60(2H,m), 6.61(1H,s), 7.08(1H,s), 7.16(1H,s), 7.38(1H,m), 7.43-7.50(3H,m), 7.58(1H,t,J=7.6Hz), 7.62-7.67(2H,m), 7.69-7.74(2H,m).

Example 84: 2-Amino-6,7-dimethoxy-4-[3-(3-pyridyl)phenyl]quinoline

[0307]




[0308] Starting from 180 mg of 2-amino-4-(3-bromophenyl)-6,7-dimethoxyquinoline obtained in Production Example 20 and 92 mg of 3-pyridyl boric acid, 95 mg of the title compound was obtained as a pale yellow oil in the same manner as in Example 48.

MASS 358 (MH⁺)

¹H-NMR (400MHz, CDCl₃)δ: 3.79(3H,s), 4.01(3H,s), 4.61(2H,m), 6.61(1H,s), 7.03(1H,s), 7.17(1H,s), 7.39(1H,m), 7.54(1H,m), 7.63(1H,t,J=7.6Hz), 7.68-7.72(2H,m), 7.93(1H,m), 7.92-7.95(2H,m), 8.62(1H,dd,J=4.8,2.0Hz), 8.92(1H,dd,J=2.0,0.8Hz).

Claims

1. A nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof.



Wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents:

- 1) a saturated hydrocarbon ring which may have a substituent group,
- 2) an unsaturated hydrocarbon ring which may have a substituent group,
- 3) a saturated heterocyclic ring which may have a substituent group or
- 4) an unsaturated heterocyclic ring which may have a substituent group,

R¹ represents:

- 1) hydrogen atom,
- 2) a halogen atom,
- 3) a C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₁₋₆ alkoxy group which may be substituted with a halogen atom or
- 5) an amino group which may be substituted with a C₁₋₆ alkyl group or an acyl group,

R² and R³ are the same as or different from and represent:

- 1) hydrogen atom,
- 2) a C₁₋₆ alkyl group which may have a substituent group,
- 3) a C₃₋₇ cycloalkyl group which may have a substituent group,
- 4) a C₂₋₆ alkenyl group which may have a substituent group or
- 5) an acyl group,

R⁴, R⁵, R⁶ and R⁷ are the same as or different from and represent:

- 1) hydrogen atom,
- 2) a halogen atom,
- 3) a C₁₋₆ alkyl group which may be substituted with a halogen atom,
- 4) a C₃₋₇ cycloalkyl group which may have a substituent group,
- 5) an aryl group which may have a substituent group,
- 6) a C₁₋₆ alkoxy group which may have a substituent group,
- 7) a C₃₋₇ cycloalkoxy group which may have a substituent group,
- 8) an aryl alkoxy group which may have a substituent group or
- 9) a C₁₋₆ alkyl thio group which may have a substituent group,
- 10) a hydroxyl group,
- 11) an amino group which may be substituted with a C₁₋₆ alkyl group or an acyl group,
- 12) a nitro group,
- 13) a cyano group,
- 14) a carboxyl group or
- 15) a C₁₋₆ alkoxy carbonyl group, or

16) neighboring R^3 , R^4 , R^5 and R^6 may be combined to form a ring which may be substituted with a C_{1-6} alkyl group, and the ring may form a heterocyclic ring containing one or more atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom,

L represents:

- 1) a single bond,
- 2) a C_{1-6} alkylene group which may have a substituent group,
- 3) a C_{2-6} alkenylene group which may have a substituent group,
- 4) a C_{2-6} alkynylene group which may have a substituent group or
- 5) a group represented by the formula $-E-G-$ (wherein E represents:
 - a) an oxygen atom,
 - b) a sulfur atom,
 - c) formula $-CO-$,
 - d) $-SO-$,
 - e) $-SO_2-$,
 - f) $-N(R^8)-$ (wherein R^8 represents hydrogen atom, a C_{1-6} alkyl group or an acyl group),
 - g) $-N(R^9)-CO-$ (wherein R^9 represents hydrogen atom or a C_{1-6} alkyl group) or
 - h) $-(CH_2)_m-$ (wherein m is an integer of 0 to 6) which may have a substituent group, and

G represents:

- a) a sulfonyl group,
- b) formula $-N(R^{10})-$ (wherein R^{10} represents hydrogen atom, a C_{1-6} alkyl group or an acyl group) or
- c) $-(CH_2)_n-$ (wherein n is an integer of 0 to 6)), and

X and Y are the same as or different from and represent:

- 1) nitrogen atom,
- 2) $=CH-$ or
- 3) a carbon atom which may be substituted with a C_{1-6} alkyl group which may have a substituent group, provided that X and Y are not simultaneously carbon atoms which may be substituted with a C_{1-3} alkyl group.

2. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which the ring A is a benzene ring, a naphthalene ring, a pyridine ring or a thiophene ring.
3. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which the ring B is a C_{3-7} hydrocarbon ring which may have a substituent group, an aromatic ring which may have a substituent group or an aromatic heterocyclic ring which may have a substituent group.
4. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which the ring B is a C_{3-7} hydrocarbon ring which may have a substituent group, a benzene ring which may have a substituent group, a naphthalene ring which may have a substituent group, a pyridine ring which may have a substituent group, a pyrrole ring which may have a substituent group, a quinoline ring which may have a substituent group, an imidazopyridine ring which may have a substituent group, an isoindole ring, a phthalimide ring or a benzene ring which may be substituted with an alkylene dioxy group.
5. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which the ring A is a benzene ring which may have a substituent group, and the ring B is a C_{3-7} hydrocarbon ring which may have a substituent group, a benzene ring which may have a substituent group or a pyridine group which may have a substituent group.
6. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which R^1 is hydrogen atom.
7. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which R^2 and

R³ are the same as or different from and represent a C₁₋₆ alkyl group which may be substituted with hydrogen atom or a halogen atom.

8. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which R² is methyl group or ethyl group, and R³ is hydrogen atom.
9. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which R⁴, R⁵, R⁶ and R⁷ are the same as or different from and represent hydrogen atom, a hydroxyl group, a C₁₋₆ alkoxy group which may have a substituent group, a C₃₋₇ cycloalkyl group which may have a substituent group or an aryl alkoxy group which may have a substituent group.
10. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which both R⁴ and R⁷ are hydrogen atoms, R⁵ and R⁶ are the same as or different from and represent methoxy group, ethoxy group, hydroxyl group or benzyloxy group which may be substituted with a halogen atom.
11. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is a single bond.
12. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is a C₁₋₆ alkylene chain which may have a substituent group, a C₂₋₆ alkenylene chain which may have a substituent group or a C₂₋₆ alkynylene chain which may have a substituent group.
13. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is a group represented by -N(R⁸)-CO-(CH₂)_n- (wherein R⁸ has the same meanings as defined above and n is an integer of 0 to 6).
14. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is a group represented by the, formula -N(R⁸)-(CH₂)_n- (wherein R⁸ and n have the same meanings as defined above).
15. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -CH=CH- or -C≡C-.
16. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which L is the formula -NH-CO-, -N(CH₃)-CO-, -CO-NH-, -NH-SO₂- or -NH-CO-NH-.
17. The nitrogen-containing heterocyclic compound as claimed in Claim 1, its salt or hydrates thereof, in which both X and Y are nitrogen atoms.
18. The nitrogen-containing heterocyclic compound as claimed in Claim 1, which is 6,7-dimethoxy-4-[3-(3,4-dimethoxybenzoylamino)phenyl]-2-methylaminoquinazoline, 4-[3-(3-chloro-4-methoxybenzoylamino)phenyl]-6,7-dimethoxy-2-methylaminoquinazoline, 6,7-dimethoxy-2-methylamino-4-[3-(4-pyridinecarbonylamino)phenyl]quinazoline, 6,7-dimethoxy-2-methylamino-4-[3-(6-methylaminonicotinoylamino)phenyl]quinazoline, 6,7-dimethoxy-2-methylamino-4-[3-(3-quinolyl)phenyl]quinazoline, 6,7-dimethoxy-2-methylamino-4-[3-(5-methylsulfinyl-3-pyridyl)phenyl]quinazoline, 6,7-diethoxy-2-methylamino-4-[3-(3-quinolyl)phenyl]quinazoline, 6,7-diethoxy-2-methylamino-4-[3-(5-methylthio-3-pyridyl)phenyl]quinazoline or 6,7-diethoxy-2-methylamino-4-[3-(5-methylsulfinyl-3-pyridyl)phenyl]quinazoline, its salt or hydrates thereof.
19. A phosphodiesterase-4 inhibitor which comprises the nitrogen-containing heterocyclic compound as claimed in any of Claims 1 to 18, its salt or hydrates thereof.
20. An inhibitor of production of TNF^α, which comprises the nitrogen-containing heterocyclic compound as claimed in any of Claims 1 to 18, its salt or hydrates thereof.
21. A pharmaceutical composition comprising a pharmacologically effective amount of the nitrogen-containing heterocyclic compound as claimed in any of Claims 1 to 18, its salt or hydrates thereof and a pharmaceutically acceptable carrier.
22. The pharmaceutical composition as claimed in Claim 21, which is an agent for preventing or treating diseases

against which an inhibitory action on phosphodiesterase-4 is effective for therapy.

23. Use of the pharmaceutical composition as claimed in Claim 21 for preventing and treating inflammatory diseases.

5 24. The pharmaceutical composition as claimed in Claim 21, which is an agent for preventing and treating arthritis.

25. The pharmaceutical composition as claimed in Claim 21 as an immunosuppressive agent.

26. The pharmaceutical composition as claimed in Claim 21 as an agent for preventing and treating diabetes.

10

27. The pharmaceutical composition as claimed in Claim 21 as an agent for preventing and treating asthma, autoimmune disease, allograft rejection, graft versus host disease, chronic joint rheumatism, multiple sclerosis, sepsis, psoriasis and osteoporosis.

15

28. A method of preventing or treating diseases against which an inhibitory action on phosphodiesterase-4 is effective for therapy, which comprises the step of administering a pharmacologically effective amount of the nitrogen-containing heterocyclic compound as claimed in any of Claims 1 to 18, its salt or hydrates thereof to a patient for whom an inhibitory action on phosphodiesterase-4 is effective for therapy.

20

29. Use of the nitrogen-containing heterocyclic compound as claimed in any of Claims 1 to 18, its salt or hydrates thereof in production of a phosphodiesterase-4 inhibitor.

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/JP99/00215

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁶ C07D239/84, C07D215/38, C07D401/12, C07D401/10, C07D401/04, C07D405/12, C07D409/04, A61K31/505, A61K31/47 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁶ C07D239/84, C07D215/38, C07D401/00, C07D405/00, C07D409/00, A61K31/505, A61K31/47 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS, REGISTRY (STN), WPIL (DIALOG)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, 93/07124, A1 (Eisai Co., Ltd.), 15 April, 1993 (15. 04. 93), Refer to all reference & EP, 607439, A1 & US, 5693652, A & US, 5801180, A	1-27, 29
A	JP, 40-20866, B1 (Fujisawa Pharmaceutical Co., Ltd.), 16 September, 1965 (16. 09. 65) (Family: none)	1-27, 29
A	ABDEL-HADI, A.Z. et al., "SYNTHESIS of new QUINOLINE DERIVATIVE S as ANTIMICLOBIAL AGENTS"; Pol. J. Pharmacol. Pharm.; Vol. 38, (No. 1) p99-p106 (1992)	1-18
A	JP, 58-88369, A (Sanofi S.A.), 26 May, 1983 (26. 05. 83) & FR, 2514765, A & EP, 79810, A1 & US, 4499092, A & SU, 1299511	1-27 29
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 20 April, 1999 (20. 04. 99)		Date of mailing of the international search report 11 May, 1999 (11. 05. 99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/00215

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 6-192099, A (Sumitom Pharmaceuticals Co., Ltd.), 12 July, 1994 (12. 07. 94) & WO, 94/07489, A1 & EP, 664128, A1 & US, 5646154, A	1-27, 29
A	JP, 5-2299987, A (Tanabe Seiyaku Co., Ltd.), 7 September, 1993 (07. 09. 93) & EP, 557016, A1 & US, 5342941, A	1-27, 29

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/00215

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 28 falls under the category of "methods for treatment of the human body by surgery or therapy" provided for in Rule 39.1(iv) of the Regulations under the PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)